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Abstract
RADIOMMUNOCONJUGATE FOR CANCER MOLECULAR IMAGING
By Nouri Elmekharam, MSc.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Chemical Biology at Virginia Commonwealth University.
Virginia Commonwealth University, 2021
Major Director: Professor Jamal Zweit
Department of Radiology
Over expression of Sperm Acrosomal SLLP1 Binding protein (SAS1B) on the
surface of uterine cancer and the availability of different anti-SAS1B monoclonal
antibodies (mAbs) that specifically bind to it, offered an opportunity to label these
antibodies with radionuclides for cancer imaging. Although optimizing in vivo stable
radiolabeling is challenging, imaging this type of aggressive cancer will improve the
treatment strategy. The objective of this work is to develop a radiolabeled anti-SAS1B
antibodies with Zircunum-89 (89Zr) and Copper-67 (67Cu) and determine, in vitro and in
vivo their uptake and biodistribution. Two anti-SAS1B monoclonal antibodies (SB2, and
SB5) were labeled indirectly with

89

Zr and

67

Cu, using Deferoxamine (DFO) and Para

Isothiocyanatobenzyl-1, 4, 7, 10-tetraazacyclododecane tetra acetic acid (p-SCN-BnDOTA) respectively. Different molar ratios of anti-SAS1B to the linker were investigated
for conjugation, (1:3, 1:5, or 1:10) to determine the optimum conjugation molar ratio to
take forward for labeling. The optimized conjugate was used to produce a radiolabeled
mAb which was used for both in vitro cell uptake experiments and in vivo tumor imaging
and biodistribution study. Results show specific uterine cancer cell uptake of radiolabeled
xx

xxi
SB2 and SB5 indicating the specificity of anti-SAS1B to its target SAS1B surface antigen
expressed on SNU539 uterine cancers cells.
[89Zr]-DFO-SB5 PET imaging revealed uptake in the SNU539 tumor xenograft,
albeit with minimal uptake. Uptake was also observed in bones and this is more likely due
to detachment of the

89

Zr from DFO, and subsequent accumulation in bone. The

biodistribution profile from imaging data was reflected in the ex vivo biodistribution of
[89Zr]-DFO-SB5.
The second mAb SB2 was radiolabeled indirectly using [67Cu]-DOTA and such radioconjugate was used to assess its uptake by SNU539 and Sk-OV3 cancer cell lines, which
express SAS1B antigen. The [67Cu]-DOTA-SB2 was taken up by both cell lines and this
uptake was significantly higher than that of

67

CuCl2 or [67Cu]-DOTA, indicating more

specific uptake in the case of radiolabeled Mab.
In the absence of radionuclides, the MAb SB2 was conjugated to the near-infrared
(NIR) fluorescence dye (IR800CW) to enable the potential for optical imaging. Using
fluorescence microscopy, SB2 mAb labeled with the NIR dye showed more binding to
SNU539 and Sk-OV3 and no binding to A549, which is consistent with its lack of SAS1B
expression. Presence of fluorescence signals in uterine cancer cells that express SAS1B
surface antigens compared with cells do not express SAS1B as negative control.
The labeled anti-SAS1B antibodies SB2 and SB5 were evaluated in vitro and in
vivo. The results demonstrated the specific binding of both labeled antibodies to the surface
uterine cancer receptors (SAS1B) through in vitro cell uptake and in vivo tumor uptake.

xxii
Labeled anti-SAS1B mAbs with radionuclides or fluorescent probes could yield an
imaging version of the mAb that can be used to determine SAS1B receptor status in such
tumors.

Such determination could impact more individualized treatment of SAS1B-

expressing cancers.
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CHAPTER 1: INTRODUCTION

1

2

1.1 Introduction
The challenge of accurate whole-body cancer detection and reporting on biological
changes, for example changes in tumor metabolic activity, has empowered the development of
molecular imaging paradigms. These approaches are capable of studying the biology underlying the
progression of disease and its response to therapy. Over the last two decades, molecular imaging has
played an important role in the management of cancer patients, aiding in early detection, accurate
staging, and objective monitoring of response to treatment [1]. A number of molecular imaging
modalities have been used to support cancer diagnosis and therapy. These include SPECT, PET,
MRI, and optical imaging using fluorescence or bioluminescence. These modalities have the
capabilities to image multiple targets using affinity probes labeled with different radioisotopes or
fluorescence agents. Radioisotopes based imaging engages three important components:
radioisotope, carrier, and binding target. Many radioisotopes have been used for imaging and
therapy, based on their specific properties [3]. Developments in antibodies production and
engineering has led to the availability of antibodies against a variety of targets, such as growth
factors, cytokines, and cell surface receptors, making antibodies useful in molecular imaging in a
variety of disease models [4] [5]. Targeted antibodies for tumor imaging are a promising approach
to evaluating and improving cancer therapy [6]. More than 70 such antibodies were approved by the
FDA for clinical use [5]. Many human tumors overexpress a variety of surface cell receptors which
have been used as a basis of receptor-targeted imaging [7]. Tumor receptor imaging offers valuable
information, including evaluation of the entire tumor burden as well as characterization of the
heterogeneity of tumor receptor expression. Tumor receptors have been some of the earliest targets
for tumor imaging and therapy with notable successes in cancer therapy and imaging, for example,
endocrine-related cancers such as breast, prostate, and thyroid cancers. The high affinity of
radiolabeled antibody for receptors on tumor cells has caused particular interest in targeting
2
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strategies [8]. An advantage of labeling antibodies is their well-defined structure with an abundance
of functional amino acids capable of binding to modified functional groups of a linker used for
labeling antibodies indirectly by radionuclides [9]. Although there is potential in using radiolabeled
antibodies for imaging and therapy, it is still challenging to synthesize a high yield of radiolabeling
stable in vitro and in vivo [10] [11]. Many factors can affect antibody conjugation, labeling, and in
vivo biodistribution [12].
A novel tumor-selective cell surface biomarker, SAS1B (sperm acrosomal SLLP1 binding
protein), has been discovered and patented at University of Virginia (UVA) [13]. Initially, SAS1B
was found to be expressed on ovary and oocytes and was restricted among adult tissue [14],[15]. In
addition, SAS1B was not detected in a variety of additional normal human tissues and no ASTL
expressed sequence tags have been deposited in the NCBI Unigene database from normal tissues
[13] [14]. Studies in vitro identified that the SAS1B target is overexpressed on the surface of a wide
range of aggressive malignancies such as uterine, ovarian, pancreatic, and renal cancers [13].
Different Anti-SAS1B mAbs were designed at UVA and investigated for targeting SAS1B
expressed on the surface of cancer cell lines [16]. Anti-SAS1B antibodies provide an attractive
molecular target to develop highly tumor-specific radio-immuno-pharmaceuticals.
In this project, two mAbs (SB2 and SB5) were selected for labeling with radionuclides
Zirconumm-89 (89Zr) and cooper-67 (67Cu) and used in vitro and in vivo work. The work described
here builds on the development of anti-SAS1B mAbs, carried out in our collaborator’s laboratory at
UVA, by developing a radiolabeled version of the SAS1B mAb (SB2 and SB5) and investigating its
targeting credentials and overall pharmacokinetics in vivo animal tumor model of uterine cancer.
This is being investigated through both ex vivo biodistribution and in vivo molecular imaging
studies.

3

4

1.2 Hypothesis
SAS1B antigen has been shown (in vitro) to be overexpressed on the surface of a number of
aggressive malignancies, including uterine, ovarian and pancreatic cancer. Monoclonal antibodies
have been produced against SAS1B target antigen. We hypothesize that the development of a
radiolabeled version of the MAbs would serve as a tool to study the binding of the radiolabeled Mab
to SNU539 tumors expressing SAS1B in vivo.
The overall objective is to evaluate the biological behavior and targeting of radiolabeled
anti-SAS1B mAb (SB2/SB5) in uterine cancer xenografts expressing the SAS1B protein. In order
to achieve this, a stable radioimmunoconjugate has to be developed and characterized. Both PET
and SPECT radionuclides will be used to produce radioimmunoconjugates that can be evaluated by
in vivo molecular imaging. The in vivo results obtained will complement the information obtained
from in vitro assays and unravel the kinetics of delivery, retention, and clearance following IV
administration of the radiolabeled conjugate.

This objective will be investigated through the

following specific aims.

1.3 Specific Aims.
1.3.1 Aim 1: Conjugation and Radiolabeling
The production of radiolabeled anti-SAS1B mAbs involves two steps: i) conjugation of the
bi-functional chelate to the mAb through covalent attachment; and ii) radiolabeling of the
conjugated mAb by the radionuclide. Radiolabeled conjugates were evaluated by High-performance
liquid chromatography (HPLC) with UV and Radio-detection (radio-HPLC) in terms of reaction
yields, radiochemical and chemical purity. Radio-TLC was used to determine radiolabeling yield
and determine radiochemical purity, and this method will be validated by the radio-HPLC data.
Further purification of the radiolabeled conjugate will be carried out using PD10 desalting columns
4

5
to separate the radiolabeled mAb from low molecular weight species, such as free radionuclide and
non-mAb associated radioactive signal.

1.3.2 Aim 2: In Vitro Evaluation
The in vitro cell uptake and retention of the radiolabeled mAb will be evaluated using
uterine cancers cell lines SNU539 (Seoul National University) which is expressing the SAS1B
protein expressed in the SAS1B.) Uptake kinetics was determined by incubating the radiolabeled
mAb and measuring the radioactivity, as a function of time, using radiotracer analysis. The
immunoreactive fraction of the radiolabeled mAb will also be evaluated and compared to that of the
unlabeled mAb, in order to determine the effect of radiolabeling on the immunoreactivity of the
mAb.

1.3.3 Aims 3: In Vivo Evaluation
SNU539 uterine cancer cells will be implanted subcutaneously in nude mice and allowed to
grow to produce xenografts, as tumors expressing the SAS1B target protein. The radiolabeled mAb
against SAS1B antigen will be evaluated in this model using either PET or SPECT live animal
imaging and validated by ex vivo biodistribution analysis of tissues including tumors.
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CHAPTER 2: BACKGROUND
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2.1 Cancer
According to the WHO, cancer is a leading cause of death worldwide. There were about
10 million deaths in 2020 and the estimation of new cases in 2021 was about 17 million
worldwide. The American Cancer Society estimates that in 2021, approximately 1,898,160
Americans will be diagnosed with cancer and of those, approximately 608,570 are expected to
die [2]. Poor outcomes from the disease are exacerbated by a combination of failure to detect
cancer until too late and ineffective treatment options [3].
Cancer is a broad term describing a large group of diseases that result when cellular
changes cause the uncontrolled growth and division of cells with the ability to infiltrate and
destroy normal body tissue. Normal cells have a specific life cycle, growth, division, and death
in a manner which is determined by the type of cell. A cell receives instructions to die through a
natural and beneficial phenomenon called apoptosis, which allows the body to replace it with a
newer cell that functions better [4]. Cancer disrupts the apoptosis process. Cells continue to
divide without stopping. Most cancers begin as a result of changes or mutations in the gene
which happen over a person’s lifetime, such as errors occurring during cell division or damage
to DNA caused by certain environmental exposures to chemicals, certain radiation, and specific
viruses [5]. Cancer can sometimes begin as a result of faulty genetic changes inherited and
passed down in families, but this is rare. Depending on the type of cancer, some involve rapid
cell growth while others grow and divide at a slower rate. Cancers are named based upon the
area where they begin and the types of cells they produce. Some forms of cancer result in visible
growths called tumors. Others, such as cancers of the blood, do not form tumors.
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Although advances are being made in the area of cancer diagnosis, treatment options are still
limited [6].

2.2 Cancer Imaging
Imaging plays an important role in comprehensive cancer care with many advantages
including real time monitoring, accessibility without tissue destruction, minimal or no
invasiveness, and the ability to function over wide ranges of time and size scales involved in
biological and pathological processes [7]. The major contributors to a reduction in mortality for
certain cancers are early detection and monitoring the treatment of cancer through screening
based on imaging [8]. The development in molecular imaging increases imaging speed to match
that of physiological processes [9]. For instance FDG-PET, and subsequently FDG-PET/CT, has
become a keystone in several oncologic procedures such as tumor staging and restaging,
treatment efficacy assessment during or after treatment end and radiotherapy planning [10].
Image guided and targeted minimally invasive therapy has the promise to improve outcome and
reduce collateral effects [11]. The research activities in targeted imaging of receptors, gene
therapy expression, and cancer stem cells have been increased and this might translate into
clinical use in the next decades [7],[12]. Close collaboration between academia and
biotechnology, information technology and pharmaceutical industries will lead to development of
targeted imaging and therapeutic agents.
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2.3 Cancer Treatment Modalities
Currently there are many modalities for cancer treatments, and appropriate applications
depend upon the specific type of cancer [13]. Established treatment approaches include surgery,
chemotherapy, and radiotherapy. Chemotherapy and radiotherapy have been employed for many
years to kill cancer cells, but in most cases the treatment is more effective in prolonging survival
[14].Therefore, many cases require a combination of treatments, such as surgery with
chemotherapy and/ or radiation therapy [15]. Despite dose-limiting toxicity and low specificity,
prolonged survival has been achieved for many cancer patients [16]. Unfortunately, many
patients ultimately die due to cancer recurrence, severe side effects of the treatment, or a
combination of both. A number of therapeutic approaches have been proposed in order to
minimize the chances of relapse in cancer patients [17]. These include hormone-based therapy,
gene therapy, cell-based therapy including stem cell therapy, and immunotherapy [18],[19].
Cancer treatment based on immunotherapy has been introduced to specifically target cancer
cells and minimize side effects induced by conventional treatment [20].

2.3.1 Surgery
Surgery has been the first standard of care for cancer diagnosis and treatment for more
than a century [21]. Surgery to establish diagnosis is usually done through a procedure in which
a small piece of tissue is removed and sent to a histopathology laboratory where it is examined
for the presence of cancer cells, type of cancer cells, and the stage. When cancer is diagnosed in
the early stages, surgery to remove the tumor could be the best option and completely curative
[22]. However, surgery is the only option for a solid tumor and local treatment. Therefore, the
use of surgery is dependent on the location of the tumor and the stage. When the cancer is late
stage, it has metastasized into other areas and invaded other tissues. In that case, surgery is not
9
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the only option for treatment, and in most cases, the cancer is not completely curative [22].
Sometimes surgery is done to prevent cancer when the patient is at high risk for a particular type
of cancer based on family history and genetic studies [23]. For example, surgery to remove a
breast would be appropriate in a woman with a high risk of breast cancer [24]. Also, surgery
could be done to treat a problem caused by advanced cancer. This is called palliative, or
supportive, surgery and is used along with other treatments to correct a problem that is causing
additional discomfort or disability [25]. For instance, surgery done to remove a blockage in the
abdomen when the cancer has grown large enough to block (obstruct) the intestine. In some
cases, palliative surgery is done to treat pain when the pain is hard to control with medicine
alone. In most cases when cancer is in the late stages, surgery is done not to treat or cure the
cancer but to bring relief and help the patient to feel better.

2.3.2 Chemotherapy
Chemotherapy uses chemical agents (anti-cancer or cytotoxic drugs) to inhibit vigorously
growing malignant cells [26]. Chemotherapy is a systemic method and, in most cases, is
recommended for cancer that has already spread to other areas of the body. Chemotherapy drugs
interact with cancer cells through different ways. Some of the drugs interfere primarily with
DNA synthesis and mitosis (cell cycle phases M and S), while other drugs work by preventing
cells from dividing [27]. Based on their chemical structures and the way they act, chemotherapy
agents divide into different categories. Alkylating agents were the first anti-cancer drugs used
and the most commonly-used anticancer drugs in chemotherapy [28]. These agents act during all
phases of the cell cycle, directly on DNA, causing cross-linking of DNA strands, abnormal base
pairing, or DNA strand breaks, thus preventing the cell from dividing [29]. Antimetabolites are
agents altering the function of enzymes required for cell metabolism and protein synthesis by
replacing natural substances as building blocks in DNA molecules [30] . Some anticancer agents
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are derived from plants and are called plant alkaloids. They specifically block the ability of a
cancer cell to divide and become two cells [31]. Other chemotherapy drugs called antitumor
antibiotics act by binding with DNA and preventing RNA (ribonucleic acid) synthesis [32]. The
cytotoxicity of chemotherapy drugs affects both cancer cells as well as normal cells. The drugs
destroy cells that divide rapidly under normal circumstances such as digestive tract, cells in bone
marrow and hair follicles [33],[34]. This effect is not permanent, however, as normal tissues are
able to repair themselves and continue to grow. The most common absorbed side effects are
mucositis (inflammation of the lining of the digestive tract), alopecia (hair loss), and
myelosuppression (decreased production of blood cells, hence also immunosuppression).
There are different plans to treat cancer cases. In some cases chemotherapy is used as the primary
treatment, such as in Hodgkin's disease, leukemia, Burkitt's lymphoma, localized diffuse large cell
lymphoma, Wilms' tumor, small cell lung cancer, and testicular cancer [21]. Sometimes
chemotherapy is combined with other cancer modalities to increase the effectiveness of treatment.
For example, chemotherapy is given prior to or after other treatments such as surgery or
radiotherapy as an adjuvant treatment to shrink the tumor and make it easier to resect. Adjuvant
chemotherapy is also used to reduce the risk of recurrence or prolong survival. When cure is not
possible, chemotherapy may be given as palliative therapy for the purpose of helping to make the
cancer patient's life as comfortable as possible [35].
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2.3.3 Radiotherapy
Radiotherapy remains an important modality among the standards of care for cancer
treatment. More than fifty percent (50%) of all cancer patients receive radiotherapy during their
course of illness [36]. Radiotherapy uses ionizing radiation and produces free radicals to kill
cancer cells and shrink tumors. This is accomplished by damaging the cell structure and DNA in
the cell nucleus, hence, reducing cell proliferation [37]. The most common way to deliver
radiation to cancer cells is through external beam radiation therapy. However, only limited
tumors can be irradiated by high-energy x-rays delivered by a beam to the main tumor [38]. An
alternate way using brachytherapy to deliver radiation is through internal radiation therapy,
which is done by using a solid source such as seeds, ribbons, or capsules which contain a
radiation source and placing them in the body near the tumor [39]. This is also limited to specific
type of cancer and is similar to external beam therapy. The other method to provide internal
therapy is through systematic therapy when the source of the radiation is in liquid form, allowing
the treatment to travel in the blood to tissues, seeking out and killing cancer cells. Additionally, a
more specific approach for cancer irradiation is provided by targeted radionuclides which utilize
monoclonal antibodies as a vehicle and bind to specific cancer cell antigens [40]. This increases
the therapeutic effects of antibodies and minimizes the side effects of nonspecific targeting.
Radionuclides emit therapeutic radiation such as alpha, beta particles, and Auger electron which
damage the DNA and cell content with different density of energies [41] (Figure 1). Although
radiation damages both normal cells and cancer cells, the goal of using targeted radionuclides is
to maximize the radiation dose to abnormal cancer cells, while minimizing exposure to normal
cells which are adjacent to cancer cells or in the path of the radiation [42]. Normal cells usually
can repair themselves at a faster rate and can retain normal function status faster than cancer
cells. Cancer cells in general are not as efficient as normal cells in repairing the damage caused
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by radiation treatment, which results in differential cancer cell killing.

Figure 1. Direct and indirect effect of ionizing radiation on the cell DNA.

2.3.4 Targeted and Biological Therapy
Conventional therapies such as radiation, chemotherapy, and surgery have been used as
standard care of cancer treatment for many years [43]. In addition to their potential to kill cancer,
however, there are significant side effects on healthy surrounding tissues and organs [44]. Therefore,
scientists and researchers have been working to discover methods of treatment that are capable of
killing only cancer cells while not affecting healthy tissues at the same time. As scientists and
researchers gain a better understanding of the mechanisms and metabolisms of the cells, such as
how they replicate, become malignant, their methods of obtaining the nutrients that allow them to
survive, and the biological environment of cancer cells, this understanding could lead to specific
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drugs which would stop the growth of, or even kill, very specific cells such as those that have
become cancerous [45]. This process is referred to as “targeted therapies.” It involves the use of
very specific methods which interfere with some aspect of cellular life while not harming healthy
cells. In cases where biological molecules are used, these therapies are sometimes called
“molecular-targeted drugs.”[46].
Biological therapy uses the body’s immune system, either directly or indirectly, to
specifically kill cancers cells or minimize the side effects that may be caused by cancer treatments

[47]. Biological therapy includes immunotherapy (such as vaccines, cytokines, and some
antibodies), gene therapy, hormone therapy, and some targeted therapies [48].

2.3.5 Immunotherapy
Cancer immunotherapy has emerged as a promising approach to therapy [49].
Immunotherapy approaches include the use of monoclonal antibodies (mAbs), cancer vaccines,
adoptive cancer therapy, and the immune checkpoint blockade therapy [50]. In the past decade,
cancer immunotherapy has become a new pillar of cancer treatment as a result of improvements
in our understanding of the biological interaction between cancer cells and the immune system.
This has led to the successful discovery of checkpoint inhibitor antibodies (checkpoint blockers
against CTLA4, PD-1, and PD-L1) which activate the adaptive cancer-immune response [49].
After FDA approval of two melanoma treatments, Ipilimumab and Vemurafenib, the death rate
due to melanoma decreased by 7% per year during the years 2013-2017 [51]. Treatment based
on antibodies has advanced the clinical management of multiple diseases, including cancer. The
number of therapeutic antibodies approved by the FDA has increased in the last few years [52].
Recent studies have demonstrated enhanced effectiveness of immunotherapy when combined
with radiotherapy through the “abscopal” effect [53] Yilmaz et al, 2019; Eldridge et al, 2020).
The abscopal effect describes the phenomenon that while using local radiation treatment to one
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area of metastatic cancer, cancer shrinkage may result in an untreated area as a result of the
radiation[54]. While this phenomenon was seen as a rare occurrence in the past, it has become
more frequent with the arrival of immunotherapy drugs such as checkpoint inhibitors [55]. The
combination of immunotherapy and radiotherapy is one of the new promising strategies to
minimize the side effects of nonspecific treatment [56]. This modality of treatment is referred to
as radioimmunotherapy (RIT).

2.3.6 Radioimmunotherapy (RIT)
Targeting of radionuclides with antibodies for cancer treatment and imaging has been an
active field of research since the discovery of mAbs. It has evolved with advancing technologies
in molecular biology, radiobiology, and chemistry, and many important preclinical and clinical
studies illustrate the benefits [57]. It is a systemic treatment which aims to deliver cytotoxic
radiation specifically to cancer cells while minimizing the radiation exposure to healthy tissue
[58]. The system utilizes monoclonal antibodies or its fragments as carriers which bind specific
antigens on the surface of cancer cells (Figure 2). Radionuclides emit ionizing radiation, which
can be utilized as endoradiotherapy for ionization and free radical formation [59]. This causes
significant damage to cellular structures and organelles, including the nucleus and the DNA [60].
Currently, there are some radiolabeled antibodies approved for treatment of non-Hodgkin’s
lymphoma “90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar)” [61], both of
which are anti-CD20 monoclonal antibodies coupled with cytotoxic radioisotopes. Also, 177LuDOTATATE

was

approved

for

gastroenteropancreatic

use

in

2018

[62].

While

radioimmunotherapy was quite successful for hematological malignancies, treating solid tumors
remains a challenge [63] as a result of poor tumor penetration of the antibodies and its
suboptimal pharmacokinetics while targeting cancer cell surface antigens [64].
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With all the different antibody forms made possible through molecular antibody
engineering, it is important to keep in mind that radionuclide selection may vary based on the
antibody’s biodistribution, tumor retention, and blood clearance properties [65]. Also, the type of
chelator and conjugation processes may affect antibody binding and radionuclide selection [66].
Even after radiolabeling, stability and retention of binding must be carefully tested [67].
Therefore, a number of factors including physical and chemical properties contribute to the
selection of the most appropriate radionuclide for a radioimmunoconjugate [68]. While there are
many radionuclides from which to choose, availability and cost have limited the choices for
clinical use.

Figure 2. Diagram demonstrating targeted radiolabeled antibody binding to cancer surface antigen.
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2.4 Radiolabeling Strategy
The radiolabeling strategy is to attach a particular radionuclide to a mAb, an antibody
fragment, or a minibody. It is dependent on the type of radionuclide, (e.g. halogen versus metal),
the type of antibody, and the radiochemistry approach used to produce the radio-immunoconjugate [69].

2.4.1 Radionuclides
There are many radionuclides which have been used successfully for clinical therapy
such as iodine-131 (131I), phosphorous-32 [32P], strontium-90 [90Sr], and yttrium-90 [90Y].
Table 1 shows a list of therapeutic radionuclides that have been used either in clinical or research
settings. A number of factors are considered when selecting appropriate radionuclides [68]. Such
factors include the radionuclide’s physical properties, such as the radionuclide half-life, energy
and intensity of radiation emitted, and emission characteristics, chemical properties, production
methods, and biological behavior such as dissociation from the carrier [68]. In addition, cost,
availability, and linkage chemistry play a role in choosing radionuclides for labeling the
antibody. Radionuclides can be classified as either diagnostic or therapeutic based on the
emission the radionuclide produces. Radionuclides typically used for therapy produce beta
particles, alpha particles, Auger electrons, or isomeric transition [70]. Some radionuclides can
emit these energy particles together in different ratios [71]. These emissions can irradiate tissue
volumes with multicellular, cellular, and subcellular dimensions. Radionuclide action is
described by linear energy transfer (LET) [71], which is the amount of energy deposited in tissue
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per unit path length and is termed liner energy transfer LET. Radionuclides differ in their LET
due to type of decay [72] (Figure 4). Therapeutic radionuclides vary in penetrating range and
LET, and again depend on the type of decay. Some decay in the form of alpha (α )- or betaparticles (β ), or Auger electrons (AEs) and electron magnetic radiation in the form of X-ray or
γ ray [71]. Additionally, some radionuclides emit positrons or γ rays. Therefore, they are useful
for imaging using positron emission tomography (PET) (e.g.15O, 13N, 11C,18F,89Zr, 64Cu and
52

Mn) or single-photon emission computed tomography (SPECT) (e.g.123I and 99mTc and 111In)

[70]. Furthermore, theranostic radionuclides are radionuclides which emit both particulate (e.g.
beta or alpha particles) radiation as well as electromagnetic radiation , (e.g. gamma-rays) for
therapy and imaging (diagnosis) respectively such as
111

67

Cu, 67Ga,

99m

Tc,

177

Lu,

111

In,

123

I, and

At [70].

Table 1. Main radionuclides which are currently used in Radioimmunotherapy adapted from
Reference [73].
Isotope

Half-life
Maximum
(T1/2)
(keV)
β−-emitters (LET: 0.2 keV/μm)
90
Y
2.67 d
2280.0
131
I
8.02 d
606.31
177
Lu
6.65 d
498.3
67
Cu
61.83 h
577.0
186
Re
3.72 d
1069.5
188
Re
17.01 h
2120.4
Auger emitters (LET: 4–26 keV/μm)
111
In
2.80 d
26
67
Ga
3.26 d
9.6
195m
Pt
4.02 d
64
125
I
59.41 d
31.7
α-emitters (LET: 50–230 keV/μm)
213
Bi
45.59 min
8400
212
Bi
60.54 min
7800
211
At
7.21 h
7500
212
Pba
10.64 h
7800
225
Ac
9.92 d
8400
227
Th
18.7 d
7400

energy Maximum
(μm)

range Emission type

11,300
2300
1800
2100
4800
10,400

β−
β−, ɣ
β−, ɣ
β−, ɣ
β−, ɣ
β−, ɣ

17
3
76
20

Auger, ɣ
Auger, β−, ɣ
Auger
Auger, ɣ

90
100
80
100
90
70

α, β−, ɣ
α, β−, ɣ
α, EC
α, β−, ɣ
α, β−, ɣ
α, β−, ɣ
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2.4.1.1 Alpha-Emitting Radionuclides (α-decay)
Some unstable atomic nuclei dissipate excess energy by emitting an alpha particle
(helium nucleus) because alpha particles have two positive charges and a mass of four units. The
emission from nuclei produces daughter nuclei having a positive nuclear charge or atomic
number two units less than their parents and a mass of four units less (Scheme 1).
Alpha-emitting radionuclides are a promising type of radiotherapeutics which show great
potential in the treatment of a broad range of malignancies [74]. Alpha particles have high
kinetic energy (5-8 MeV) and their range in tissue is about 40-80 µm. An Alpha particle is an
helium atom and its nucleus consists of two protons and two neutrons [75]. Alpha particles have
a high linear energy transfer (LET) value of 50-230 keV/µm [76] (Figure 4). As a consequence
of their high LET, they have greater relative biological effectiveness (RBE) and require less
radiation per cell kill than beta particles or x-rays [77]. The path length of alpha-particles is
short, so the energy deposited is limited to a few cells. Thus, they are capable of destroying
tumors while causing very limited damage to the surrounding healthy tissue [78]. These
properties seem to be ideal for treating small cells, such as in micro-metastatic cancer [74].
Alpha-emitting radionuclides offer the exciting prospect of matching the cell-specific nature of
molecular targeting with radiation of

19

20

a similar range of action [74]. However, for alpha therapy to be effective, the radionuclide decay
needs to take place at close proximity to the cell or inside the cell. This is dictated by the quality
of the site specific targeting molecule, such mAb [79].

Scheme 1 Alpha decay

2.4.1.2 Beta-Emitting Radionuclides (Negative Beta decay (β- -decay))
Negative beta particles are emitted when the nucleus of radioisotopes have an excess
number of neutrons. The neutron will convert to proton and emit beta particles which are an
energetic electron (of relatively small mass) and an antineutrino which has no rest mass nor
electric charge and does not interact readily with matter (Scheme 2). Therefore, the atomic
number of this nucleus will increase by one and the mass number will remain the same. These
are negative beta particles or negatively charged electrons emitted from the nucleus and their
energy in tissue varies from zero up to maximum [60].
About one-third of the maximum energy is equal to the average energy of β− particles
energy [68]. β− particles energy ranges from 0.05 to 2.3 MeV, and they have low LET of about
0.2 keV/µm with a long penetrating range in tissue (1 mm to several mm) [80] (Figure 4). This
causes limited ionization and DNA damage involving single-or double-strand DNA breaks, base
chemical modifications, and protein crosslinks [80]. Consequently, disregarding other
parameters, such as tumor penetration profiles of radionuclide carriers, higher radionuclide
concentrations of beta emitters than alpha emitters are required for comparable cell kill.
β− particles emitters such as 177Lu, 90Y and 131I have been used in cancer treatment [81].
However, the long beta particles’ path that crosses multiple individual cells might cause a
“crossfire” effect by energy disposition in normal tissue [71]. Cell survival studies show that
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cells are more sensitive to radiation when they are arrested in the G2 phase and are in a good
oxygenated state (35). The presence of oxygen upon beta particle irradiation generates free
radical species that are particularly harmful to the nuclear DNA. Both the rate of beta particle
disintegration (half-life) and amount of radioactivity at the target site influence the killing
efficacy by competing against the enzymatic repair of the irradiated DNA strands.

n → p + e- + v-e

Scheme 2 Negative beta decay

2.4.1.3 Beta-Emitting Radionuclides (β+-decay) (Positron emission)
When some of the unstable radioisotopes nucleus have an excess number of protons, these
protons will convert into neutrons in order to stabilize the nucleus [82] (Figure 3). A proton in the
parent nucleus decays into a neutron that remains in the daughter nucleus, and the nucleus emits a
neutrino and a positron. The neutrino has no electric charge nor rest mass, while the positron is a
positive particle like an ordinary electron in mass but of positive charge. Therefore, positive beta
decay produces a daughter nucleus, and in each decaying nucleus emits a positron and a neutrino,
reducing its atomic number by one while the mass number stays the same. The positron does not
exist for a long period of time in the presence of matter. It will travel a short distance before
colliding with an electron of a nearby atom, with which it undergoes annihilation. This annihilation
will emit electromagnetic energy in the form of two 511-keV gamma rays that are emitted in almost
opposite directions [82] (Figure 3). These are useful photons for imaging because they easily escape
from the human body and can be recorded by external detectors. When two opposite gamma-rays
detected following the disintegration of positronium, this is called a coincidence line. These
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coincidence lines offer a unique detection scheme for forming tomographic images with PET. Many
radioisotopes decay by positron, such as underging this decay and thereby emit positrons including
carbon-11, nitrogen-13, oxygen-15, fluorine-18, copper-64, gallium-68, bromine-78, rubidium-82,
yttrium-86, zirconium-89, yttrium-90,[3] sodium-22, aluminium-26, potassium-40, strontium-83.

p → n + β+/e + ve

Scheme 3 Positive beta decay

Figure 3. Schematic illustration of an annihilation reaction in tissues. A positron emitted from the
nucleus and then annihilates with an electron to produce two gamma rays in opposite direction.
Adapted from ref [83].
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2.4.1.4 Electron Capture (Inverse Beta Decay)
In this process, a proton-rich unstable nucleus similar to positive beta decay. However, it
reduces its nuclear charge to one unit by absorbing an atomic electron to convert the proton to a
neutron and a neutrino. The proton captures an electron from the K or L shell. This process reduces
the atomic number by one and emits gamma radiation or an x-ray and auger electrons. When the
electron is absorbed from the electron orbit, the outer orbital electron will fill the vacancy. This will
set off a cascade of electron transitions with their associated characteristic x-rays emission. The
transition of losing the outer orbital electron, will result in releasing of energy. When this energy
transferred to another electron, the electron will be ejected from the atom and this electron is called
an Auger electron [84].

p + e --> n + ν.

Scheme 4 Electron capture decay

2.4.1.5 Auger-Emitting Radionuclides
Auger electrons are low energy atomic orbital electrons emitted following electron
capture (EC) decay [79]. They have short ranges of 1-2µm and a high LET. However, they need
to be internalized into the cell nucleus to be most effective [79]. If internalized, their high LET
means they can be profoundly cytotoxic. Recent work to improve Auger therapy has led to the
development of fusion proteins incorporating a nuclear localization sequence (NLS) [70]. The
LET of Auger electrons range between 4 and 26 keV/μm (figure 4). This high energy produces
clustered damage in DNA and the cell membrane [84]. Also, many of AE-emitting
radionuclides emit a small number of internal conversion IC electrons which have high energies
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and transfer in several millimeters [84].There are many Auger-emitting radionuclides which
have been used in nuclear medicine (e.g. 99mTc, 123I, 111In) [74].

Figure 4. Illustration of the track of α-particles, β-particles or Auger electrons emitted by
radiolabeled monoclonal antibodies targeted to cancer cells. The short track length of α-particles
(28–100 μm) and Auger electrons (<0.5 μm) results in high linear energy transfer (LET) values
of 50–230 keV/μm and 4 to 26 keV/μm, respectively. β-particles have a track length of 2–10 mm
resulting in LET of 0.1–1.0 keV/μm. The high LET of α- particles (50–100 μm) and Auger
electrons make these forms of radiation more powerful for killing cancer cells than βparticles.Adapted from ref [74].
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2.4.1.6 Gamma (γ) Decay
This is an electromagnetic radiation usually followed alpha and beta decays. When the
radioactive nucleus emits alpha or beta particles, the new daughter nucleus left is in an excited state
and will release energy to allow the proton or neutron to relax back down to ground state. During
this transition from a high to a low energy state gamma photon is emitted. Gamma rays are photons,
or packets of high electromagnetic energy of extremely short wavelength. The energy of gamma
rays ranges from a few keV to ~8 MeV, corresponding to the typical energy levels in nuclei with
reasonably long lifetimes. This type of decay does not change the structure or composition of
the atom. It only changes the energy because it does not carry any charge or associated mass.
Gamma decay includes two other electromagnetic processes, internal conversion and internal pair
production. In internal conversation, it always accompanies the predominant process of gamma
emission to some extent. This takes place when the excess energy in a nucleus is directly transferred
to one of its own orbiting electrons and, as a result, the electron is ejected from the atom. Internal
pair production happens when the excess energy is directly converted within the electromagnetic
field of a nucleus into an electron and a positron (positively charged electron) that are emitted
together. Gamma radiation is emitted by many natural radioisotopes and is also produced artificially
in fission in nuclear reactors, high energy physics experiments, nuclear explosions, and accidents.
Although gamma rays are harmful due to the fact that they are generally very high energy and,
therefore, penetrate matter very easily, it is useful radiation for medical and other purposes. Gamma
rays have been used in medicine (radiotherapy and diagnosis), industry (sterilization and
disinfection) and the nuclear industry. Gamma rays produce photons indirectly through gamma-ray
photon-electron interactions as the gamma radiation travels through a transparent medium. These
photons are useful for imaging used by both single photon emission computed tomography (SPECT)
and Positron Emission Tomography (PET).
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2.5 Antibodies
Due to the affinity, specificity, and selectivity, antibodies and antibody fragments,
including minibodies, make attractive vehicles for delivery of radionuclides to tumors for
imaging and therapy [85]. Monoclonal antibodies are macromolecules and, therefore, have
longer biological half-life because of their size. This enables them to match and label long
radioactive decay half-life radionuclides [86].
Monoclonal antibodies (mAbs) are about (150 kDa) (Figure 1), while antibodies
fragments <150 kDa (e.g VH or VL domains (15 kDa), scFv (30 kDa), Fab (50 kDa) and Fab’2
(110 kDa (as shown in Figure 5) [85]. Large size antibodies have a longer circulation time than
smaller fragments [85]. Monoclonal antibodies are complex molecules comprised of two
identical light chains and two identical heavy chains held together by disulfide bonds.
Consequently, they form a Y-shaped molecule containing two identical antigen-binding arms
(Fabs) and a glycosylated stem region (Fc) separated by a flexible hinge region (Figure 5). The
Fc region is responsible for the recruitment of cytotoxic effector mechanisms, including the
activation of a complement cascade and interactions with Fc-receptors on immune cells [85]. The
Fc also furnishes mAbs with an unusually long serum half-life of several days or weeks through
interactions with neonatal Fc receptors [86]. Atypical antibodies consist of about 80% of lysin
residuse [87].The advanced technology in antibody engineering has led to producing humanized
mAb and its fragments and has improved the conjugation, tumor penetration, and targeting
affinity [87]. The use of mAbs is well established and currently more than 150 of them are in
clinical development [52]. In this project monoclonal SAS1B antibodies were used for
radiolabeling and near-infrared dye labeling.
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Figure 5. Monoclonal antibody and antibody fragments. Left: Y-shaped structure of antibody. The
Fc domain consists of the constant part of the two heavy chains, while the Fab domain consists of
the variable part of the heavy chain and the light chain. Right: Native and engineered antibody
fragments. Adapted from reference [88].

2.6 Radiochemistry of Radiolabeled Antibodies
Radiolabeling of antibodies can be done either directly or indirectly. While halogenbased radionuclides can be used to directly label antibodies, metal-based radionuclides require a
linker (chelator) molecule to conjugate to the antibody [89]. For example, iodine radionuclides
are used to either directly label antibodies by electrophilic substitution or indirectly via a
conjugation group (Figure 6-A). Most other radionuclides label antibodies indirectly via prostatic
group (Figure 6-B) or via complexation by a chelator (Figure 6-C).
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Figure 6. Radiolabeling Strategies A) Direct labeling. (B and C) Indirect labeling. Adapted from Ref
[90].

Metal radionuclides, such as zirconium-89, Indium-111, and lutetium-177, require a
chelator molecule to label monoclonal antibodies indirectly [89]. There are a wide range of
bifunctional chelators. BFCs have been developed for conjugation of targeting constructs with
several radionuclides. It is important that BFC produce a large, expedient, and stable yield in
radiolabeling [91]. The selection of which radiochemical method to use to prepare
radioimmunoconjugates is based on the physiochemical properties of the radionuclide [89]. For
instance, the short half-life of some radionuclides does not allow for lengthy reaction conditions,
and additional purification steps are unfavorable. Due to the diverse properties and coordination
chemistry of radionuclides, it is difficult to design a chelating agent which can bind to all
radionuclides. Moreover, selection of BFCs is largely determined by chemical properties, such as
oxidation state and coordination chemistry [91], and the resulting radiopharmaceutical must have
high solution stability. Therefore, BFCs must form a metal chelate with high thermodynamic
stability and kinetic inertness in vitro and in vivo to avoid both accumulation of radioactivity in
normal tissue and interaction with ions available in vivo [91]. Several macrocyclic agents have
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been developed for stability of frequently based radionuclide complexation. There are different
approaches to conjugating chelator to antibodies. The functional group of the chelator could be
an aromatic isocyanate or an activated ester, which will react with nucleophilic sites (-NH2,-SH,
or –OH) of antibody [92]. For example, p-SCN-Bn- DOTA c(S-2-(4-Isothiocyanatobenzyl)1,4,7,10-tetraazacyclododecane tetra acetic acid ), a chelator with isothiocyanate, reacts with the
N-terminal amino group of the antibody, additional lysine resides, and even arginine residues
[93]. On the other hand, when it reacts with metal ions of radionuclide, DOTA makes a complex
structure by coordinating the nitrogen atom of the cyclen ring and carboxy groups of the acetate
arms [93]. It is useful to know the sites of crosslinking, as well as the amino acid residues in
monoclonal antibodies which bind to the functional group in chelator when choosing the
appropriate chelator with specific functional group. This can help avoid undesirable binding of
chelator with the antibody, such as binding to Fab regions which may lead to nonspecific binding
inside the body [91]. It is necessary to ensure that the conjugation of a chelator to the antibody
does not lower the antibody-receptor binding. When the active sequence that confers binding
affinity is known, the conjugation can be directed. Moreover, conjugation efficiency depends on
optimizing ratio of chelator to monoclonal antibody, pH, time, and the temperature of the
reaction [91].
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CHAPTER 3: MOLECULAR IMAGING
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3.1 Molecular Imaging
Molecular imaging is an attractive approach that enables noninvasive visualization,
characterization, and quantification of biological processes (events) taking place at the cellular
and subcellular levels in humans and other living systems. Molecular imaging contributes in
clinical diagnosis, staging of the disease, treatment, and surgery plan [94]. Molecular imaging
can also provide quantitative information which plays an important role in monitoring cancer
status over time or in treatment [95]. There are several techniques that are well established
imaging modalities. These include techniques based on radiation, optical, nuclear magnetic
resonance, and ultrasound properties (Table 2). MRI and computed tomography (CT) depend
solely on energy-tissue interactions, whereas others such as PET or optical imaging require the
administration of radionuclides or optical probes [95]. Positron emission tomography (PET) and
single-photon emission computed tomography (SPECT) are of great interest from the view of
high sensitivity as nuclear medical imaging, distribution, and kinetics of a radiolabeled molecular
probe in which a radioactive molecular probe is administered into the body [96]. The other
attractive methodology is optical molecular imaging which depends on light photons at different
wavelengths from visible and infrared ranges resulting from fluorescent and bioluminescent
events. For instance, using fluorescent probes that can be detected by using a fluorescent imaging
instrument to study distribution and kinetics. This technique does not involve exposure to
ionizing irradiation and provides real-time imaging with high spatial resolution inexpensively
[97],[98]. The most common imaging techniques and their important characteristics and
applications are listed in table 2. Each of these imaging tools brings its own advantages and
disadvantages. In order to obtain optimal performance, in most cases the suggestion is to use
more than one modality, either in series or combined in one hybrid modalities, e.g., PET/CT or
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PET/MR [99],[100]. Most image modalities depend on identifying the imaging target and
selecting an appropriate imaging contrast agent or ligand. Based on specific properties, imaging
targets can range from cell surface markers or genes and their related products to a particular
cellular or pathological process [96]. Usually the agent is in the form of a small molecule,
protein, or antibody that can bind to or enter the target environment upon injection into the
subject body [101]. In recent years, multimodality probes have been increasingly common for
improvements in efficiency.
Table 2.The most common imaging modalities.
Modality

Spatial

Advantages

Disadvantages

Sensitivity

resolution

Depth of

Type of

Probe

penetration

molecular

quantity

probe
CT

50-200um

High spatial resolution
penetration depth, fast and
cross-sectional image
High sensitivity; excellent
penetration depth; wholebody imaging
High sensitivity; no tissue
penetration limit; no need
for cyclotron

PET

1-2 mm

SPECT

1-2 mm

MRI

25-100um

High spatial resolution no
tissue penetrating limit
No radiation

Optical
fluorescence
imaging

2 – 3 mmd

High sensitivity ;
no radiation; inexpensive
activalable

Optical
bioluminescence
imaging

3-5mmd

High sensitivity; no
radiation; inexpensive and
simple equipment
operation; non-damaging
imaging

Ultrasound

50-500um

No radiation; excellent
sensitivity with
microbubbles; high
temporal resolution;
inexpensive

Low contrast,
radiation risk

10-8

Limitless

May be
possible

Not used

High cost of
cyclotron needed;
radiation risk
Low spatial
resolution;
radiation risk;
hard to quantify
Relatively low
sensitivity and
low contrast:
high cost :long
scanning time
Low spatial
resolution
attenuation by
overlying tissues;
poor penetration
depth
Low spatial
resolution
attenuation by
overlying tissues;
poor penetration
depth
Poor penetration
depth;
High spatial
resolution; low
contrast and
strong boundary
effect

10-11-10-12

Limitless

Nano grams

10-9-10-8

Limitless

Radiolabeled
, directly or
indirectly
Radiolabeled
, directly or
indirectly

10-9-10-8

Limitless

10-9-10-12

<1cmf

Activatable,
directly or
indirectly

MicrogramMilligram

10-15-10-17

1-2cm

Activalable
indirectly

MicrogramMilligram

Excellent
when
microbubble
s used

MillimetersCentimeters

Limited
Activatable,
directly

MicrogramMilligram

10-2-10-5

Nano grams

MicrogramsMilligrams
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3.1.2 Positron Emission Tomography (PET)
Positron Emission Tomography (PET) is widely used as a molecular imaging approach
for research and clinical needs using different radionuclides Table 3. PET is a minimally
invasive imaging procedure with a wideranges of clinical and research applications. PET allows
for the three-dimensional mapping of administered positron-emitting radiopharmaceuticals such
as 18F-fluorodeoxyglucose (for imaging glucose metabolism). Also, PET enables the study of
biologic function in both health and disease. In addition molecular imaging with PET allow the
visualization of various molecular pathways including metabolism, prolife-elation, oxygen
delivery and consumption, and receptor or gene expression, all of which may be important in the
response to ionizing radiation[102]. Furthermore, PET can be used to evaluate novel
radiolabeled PET imaging agents, effectiveness of new therapies, and biodistribution of novel
pharmaceuticals in suitable animal models.
PET is based on using the advantage of the unique properties of radioactive isotopes that
decay via positron emission. The nucleus of these radioisotopes has an excess of protons and, in
order to reach stability, protons transform into a neutron, a positron, and a neutrino. The newly
formed short-lived positron is ejected from the nucleus and interacts with an electron from the
surrounding environment after traveling a distance. This is called positron annihilation, resulting
in the emission of two 511 keV gamma rays traveling in opposite directions (Figure 7 and 8).
Image acquisition is then based on simultaneous detection (coincidence detection) of these two
gamma rays Figure 9. By acquiring a large number of such events, tomographic reconstruction
methods can be used to reconstruct two dimensional images of the tracer distribution.
PET scans are now routinely combined with computed tomography (PET/CT) or magnetic
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resonance imaging (PET/MRI). The functional metabolic imaging of PET is fused with the
anatomical structure imaging of CT or MRI, which can obtain information such as function and
metabolism, and can also have high spatial resolution and accuracy. Moreover, a variety of PET
radiotracers have been introduced.
Table 3.Most comomly used PET radionuclides.
Radinuclide
15
O
13
N
11
C
18
F
68
Ga
64
Cu
89
Zr
76
Br
124
I

Imaging modality
PET
PET
PET
PET
PET
PET
PET
PET
PET

Half-life
2.05 min
9.96 min
20.4 min
109.7 min
67.6 min
12.7 h
78.4 h
13.1 h
4.18 days

Figure 7. Small animal positron emission tomography (PET). A: schematic illustrating the basic principles of PET.

First, a targeted imaging agent (e.g., small molecule, peptide, engineered protein, aptamer, nanoparticle) containing a
positron emitting radioisotope is administered to the subject.
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Figure 8. Illustration of an annihilation reaction in tissues and the subsequent coincidence detection
in PET detector. Adapted from reference [103].

3.1.2.1 Coincidence Detection
PET records only true coincidence events that originate as a result of positron annihilation
along the line between the two parallel opposite detectors (Figure 9-A). These events carry
information regarding the spatial location of the positron source. The detector pair should ideally
produce signals simultaneously. In cases of true coincidences, but due to limitations of scintillation
detector as well as associated electronics, coincidence events are accepted within a finite interval
which is of the order of 4 to12 ns. Therefore, two unrelated photons may be detected and get
registered as coincidence events (Figure 9-B). These events are called random or accidental events
and they provide useful information regarding spatial location of activity distribution which needs to
be corrected. These accidental events cause noise and increased background in the final images. In
addition, sometimes both of the annihilated photons are diverted from their original direction as a
result of Compton interaction and reach the detector to misposition the coincidence event as shown
(Figure 9-C).
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A-True coincidence events

B-Random or accidental events

C-Scattered coincidence events

Figure 9. Types of coincidence events. True coincidence detection occurs when the two gamma rays
are detected from one annihilation event in the time window. Random coincidence occurs when both
photons detect in the time window and are from deferent annihilation events. scattered coincidence occur
when at least one of the gamma photons under goes Compton scattering, and both photons still detected
in the time window.

3.1.2.2 Production and Applications of PET Radionuclides
Positron sources are produced artificially because they are not stable in nature. They are
produced by bombarding stable isotopes with positively charged particles. This requires using a
cyclotron to generate short-lived radionuclides such as 18F (t1/2 = 109.8 min), 64Cu (t1/2 = 12.7 h),
and 76Br (t1/2 = 16.2 h), or ultra-short-lived radionuclides such as 11C (t1/2 = 20.3 min), 13N (t1/2 =
10 min), and

15

O (t1/2 = 2.04 min) (143). There many radionuclides that have been used for

preclinical and clinical. Table 4 lists some of the most used PET radioisotopes.
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Table 4. Example of some radionuclides production.
Radioisotope
F-18
I-124

Half-life (h)
1.8
100.3

Decay mode (%)
EC β+(97), (3)
β+(23), EC(77)

Cu-64

12.7

β+(19),
β−(40),
EC(41)

Ga-68

1.1

β+(89),
EC(11)

Zr-89

78.4

β+(23),EC(77)

Application
18F-FDG
Imaging (PET)
Thyroid cancer,
Cardiovascular
imaging [124I]-MIBG
Imaging (PET);
Therapy
Prostate cancer
[64Cu]-NODAGAPSMA)
Imaging (PET)
Neuroendocrine
tumors
[68Ga]-DOTATOC,
[68Ga]-DOTATATE
Imaging (PET)
Variety of cancerrelated targets (HER2,
ER, PSMA

Usually PET scans are combined with computed tomography (PET/CT) or magnetic
resonance imaging (PET/MRI). This provides functional metabolic imaging of PET and anatomical
structure imaging of CT or MRI, so in addition to the information of the function and metabolism, it
will have high spatial resolution and accuracy.
Positron Emission Tomography (PET) has emerged as one of the greatest tools used for
clinical applications (Table 5). FDG PET being better than MRI and CT in detecting lymph node
metastasis from SSC [104]. Providing metabolic functional imaging and pathologic processes by
using PET images opened newer options for incorporation of this information into patient
management protocols. Table 5 shows some useful clinical applications using PET scan.
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Table 5. Commonly used PET tracers for clinical molecular imaging of diseases. Adapted from
reference [105].
Medical Imaging

Molecular Target

Radiotracer(s)

Oncological Imaging

Protein synthesis

11

Glucose transporter

11

Choline transporter

11

Neurological Imaging

C Methionone,

Protein synthesis in tumors

C-DG, 18F-FDG

Glucose metabolism in tumors

C-choline

thymidine
uptake
DNA/RNA synthesis

Cardiovascular Imaging

Clinical Applications

in

Tumor phospholipid synthesis

F-FLT, F-FMAU; F-FU

Tumor cell proliferation

18

18

18

αVβ3 integrin

18

F-galacto-RGD

Tumor angiogenesis

HSV1-tk

18

F-FHBG

Suicidal gene therapy

Hypoxia

18

F-FMISO; 64Cu-, 60CuATSM

Tumor hypoxia

Somatostatin receptor

64

Estrogen receptor

18

Androgen receptor

18

Cell metabolism

11

Fatty acid metabolism

11

Adrenergic
neurotransmission

11

Cardiac
Neurons

18

Dopamine
receptors

Sympathetic
post

synaptic

Cu-TETA-octreotide

Neuroendocrine tumors

F-FES

Breast Cancer

F-FDHT

Prostate Cancer

C Acetate

Cardiac metabolism

C Palmitate

Ischemia

C Metahydroxy-ephedrine

Heart failure

F Norephinephrine

Cardiac
innervation

C Raclopride

Schizophrenia, Addiction

C-PIB

Alzheimer’s disease

11

β-amyloid

11

NK-1 Receptor

18

Dopamine transporter

18

Dopamine metabolism

18

sympathetic

F SPARQ; C-R116301

Depression, Anxiety

F FECNT

Schizophrenia, Addiction

F DOPA

Schizophrenia, Addiction

11

3.2.2 Single photon emission computed tomography SPECT
Single photon emission computed tomography (SPECT) is a nuclear medicine imaging
technique using gamma rays. SPECT provides a 3D image to visualize and measure biological
processes within living systems. The basic principle for SPECT is based on using the advantage
of nuclides such as

99m

Tc (t1/2 = 6 h),

123

I (t1/2 = 13.3 h), and

111

In (t1/2 = 2.8 days), which

decay via the emission of single gamma rays with differing energies. When the radionuclide
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emit gamma-ray inside the body, it can be detected using a single or a set of collimated radiation
detectors[106].Two or three gamma cameras rotate and detect gamma rays produced by
radionuclides from different angles. The detectors used in current SPECT systems mostly
depend on a single or multiple NaI (TI) scintillation detectors [106]. When gamma rays produce
light photons (415nm) which enter the scintillator and ionize the iodine atoms, these photons are
converted to an electrical signal which is then recorded and used to reconstruct multiple twodimensional images and generate cross-sectional images [107]. In SPECT, projection data are
acquired from different views around the animal or patient (Figure 10 &11). Table shows the
most common used radionuclides and it applications.
Table 6. Most commonoly used SPECT radionuclides.
Radioisotope
Tc-99m

Half-life (h)

Decay mode (%)

Ga-67

78.3

EC(100), γ

I-123

13.2

EC(100), γ

In-111

67.2

EC(100),
Auger, γ

Lu-177

159.5

β−(100), γ

Cu-67

62

β−(100), γ

6.0

IT(100), γ

Application

Used for diagnostic
imaging many types of
cancer
Imaging
(SPECT)
Imaging
(SPECT) Thyroid cancer
Imaging
(SPECT);
Therapy
Widely used in clinical
practice for diagnosis
Imaging
(SPECT);
Therapy
177
Lu DOTATATE
SPECT imaging and
therapy
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Figure 10. Small animal single photon emission computed tomography (SPECT). A: diagram
illustrating the principles of SPECT, i.e., a targeted SPECT imaging agent (containing a gamma
emitting radioisotope) is administered to the subject and the gamma rays are detected via a gamma
camera (rotated around the subject).

Figure 11. Illustration of the basic principle of SPECT imaging.
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3.3 Optical Imaging
Optical imaging techniques offer simplistic while highly sensitive modalities for
molecular imaging research. Non-invasive images help with identification and localization of
tumor lesions and characterization of processes involved in tumor proliferation and invasion,
concurring to the description of tumor features, staging, treatment evaluation, and as imageguided-surgery[108].
Images are generated by using photons of light in the wavelength range from ultraviolet
to near infrared. The contrast of optical images can be derived through using exogenous agents
such as dyes or probes, or by using endogenous molecules which can provide a signal such as
NADH, hemoglobin, collagens, and reporter genes [109]. The strategies of optical imaging are
based on the use of injectable fluorescent or luminescent probes that provide the possibility to
study tumor features. Currently, most of these probes are used only in animal models, but the
possibility of applying some of in clinics also is under evaluation [108].

3.3.1 Fluorescence molecular imaging (FMI)
Fluorescence molecular imaging (FMI) is emerging as a technology with substantial
potentials that enable in vivo imaging of molecular and cellular processes with high
sensitivity[110]. FMI has gained great popularity over the past decade, mainly because of its safe
and straightforward use. The application of fluorescence molecular imaging would also help
bioengineering scientists investigate disease processes, evaluate therapy response, and develop
new drugs. FMI is based on using an engineered imaging of fluorescence agents to target specific
disease biomarkers. When fluorescence agents are excited with a light source, fluorescence is
emitted as photons during the return to a ground state of electrons excited by photo-stimulation.
These photons can be revealed by a high sensitivity camera (CCD mainly) through appropriate
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band-pass filters to block photons at the excitation wavelength and allow the recording of
photographs of emission (fluorescence) photons exiting the tissue surface. Depending on the
particular light-sensitive technology employed, there are different operational specifications and
spectral regions spanning 400–1,700 nm which can be implemented. For example, a chargecoupled device (CCD), indium gallium arsenide (InGaAs), or a complementary metal-oxide–
semiconductor (CMOS). There are also many different fluorescent agents that target
biochemical and molecular features of diseases that are being approved for experimental clinical
use. For instance, a folate receptor-targeting fluorescence agent has been used to improve
detection of ovarian cancer in patients [111]. Also, fluorescently labeled cetuximab has been
employed to improve precision in oral cancer surgery [112]. Fluorescence molecular imaging
can obtain high sensitivity detection with low instrumentation expense compared with other
molecular imaging approaches.
Moreover, a protease-activated fluorescent agent was also considered in humans for
detecting soft tissue sarcoma [113]. Additionally, using a targeted heptapeptide for
detection of colonic dysplasia and detection of Crohn’s disease using a fluorescent labelled
antibody targeting tumor necrosis factor has been demonstrated in humans [114].
Fluorescent molecular imaging can obtain high sensitivity detection with low
instrumentation expense compared with other molecular imaging approaches.
Fluorescent imaging is also used to assist surgeons in delineating malignant from benign
tissue. The increasing availability of fluorescent proteins, dyes and probes enables the non-invasive
study of gene expression, protein function, protein-protein interactions and a large number of
cellular processes [115]. This body of information has great attention for using fluorescent
molecular imaging especially using agents that emit in the near infrared fluorescence range.
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3.3.1.1 Near-infrared (NIR) Optical Imaging
High-resolution near-infrared (NIR) optical imaging has become an attractive modality
for non-invasive visualization of deep tissues. Because of its high tissue permeability, low
absorption and low scattering of NIR light as well as low auto fluorescence, near-infrared (NIR)
dyes have received increasing attention in recent years as diagnostic and therapeutic agents in the
fields of tumor research and clinical applications. They are small organic molecules that function
in the NIR wavelength region (700–1400 nm). Compared to other modalities such as magnetic
resonance imaging (MRI), X-ray computer tomography (X-ray CT), and positron emission
tomography (PET), NIR optical imaging has a high spatiotemporal resolution (∼μm) enough to
visualize cellular dynamics at the whole-body level. In addition, NIR optical imaging has no
radiation effect. Molecular imaging can also be achieved easily using NIR optical probes, such as
antibodies which specifically bind over expressed cancer cell surface antigens.

3.3.1.2 MULTISPECTRAL IMAGING Multispectral Imaging (MSI)
This is a fluorescence-based optical technique which optimizes the opportunities for
multiplexing while at the same time overcoming the effects of autofluorescence on detectability
and reliable quantitation [116]. In this technique, it is possible to acquire multispectral datasets
by simply rotating a filter wheel in front of a CCD camera. The use of electronically tunable
filters (no moving parts, continuous tunability) is also attractive. When the multispectral image
set is captured, spectral unmixing and signal quantitation and display complete the imaging
process. This system offers a high spatial resolution, good reagent flexibility, high throughput,
and compatibility with relatively high levels of multiplexing.
The Maestro™ is one of the multispectral imaging systems (CRi, Woburn, MA, 01801)
which are used for imaging small animals and their organs separately [116]. The system uses liquid
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crystal tunable filters which are band-sequential filters and easily coupled to focal plane array
detectors employing CMOS, standard CCD, or EMCCD technologies, among others. A complete
image can be acquired by sequentially tuning the filter and exposing the sensor at each wavelength.
The user can easily vary the exposure time as a function of wavelength. Therefore, this allows the
ability to optimize signal-to-noise in situations where sensitivity (emitted photons convolved by
imaging receiver characteristics) varies over the spectral range. Moreover, it is possible to maximize
signal-to-noise by acquiring only the most informative bands because the wavelengths acquired can
be arbitrarily spaced through the spectral range of interest.

3.4 Radio-immuno-Imaging
Many tumors have either unique or over-expressions of specific receptors that can be
exploited for both diagnosis and therapy [117]. Currently, there are several approved
radiopharmaceuticals specifically targeting cancer surface receptors and a major amount of ongoing
research to develop new receptor-based imaging agents (Figure 7) [118]. Tumor receptor imaging
provides complementary information which includes evaluation of the entire tumor and
characterization of the heterogeneity of tumor receptor expression. The most important element for
tumor receptor targeting is the nature of the ligand-receptor interaction [119]. There are several
considerations regarding the selection of specific radionuclide, ligand linker, and labels for different
situations. Notably, the requirement of imaging probe is that it should be low molecular
concentration to avoid saturating the receptor and increasing the background because of nonspecific
uptake, and also the metabolic stability in vivo pharmacokinetics, and imaging label
characterization. The label should remain attached to the ligand so it will not accumulate in normal
tissue. The ligand should have high receptor specificity and affinity so that it binds to the desired
receptor well and does not bind significantly elsewhere. More importantly, the label must have a
half-life that matches with the rate that the ligand binds to the receptor and clears from the
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background. Antibodies bind very effectively to specific receptors and have long half-life.
One well-known antibody example in binding to a cell receptor is capromab pendetide,
which binds specifically to the prostate specific membrane antigen (PSMA) [120]. There are many
receptors highlighted, and recent investigations of receptor imaging with other molecular imaging
modalities are reviewed. Molecular imaging of tumor receptors has been mainly confined to
radionuclide imaging (PET and SPECT), with which it is possible to generate images with
micromolar to picomolar concentrations of imaging probes. In addition, using optical imaging based
on near-infrared appears promising.
Table 7. Examples of preclinical RIT studies in solid tumors adapted from reference [71]
Target antigen
Targeting moiety
Radionuclide
Model
177
hK2
Murine Ab
Lu
Prostate cancer
213
CD138
mAb
Bi
Ovarian carcinoma
177
EGFR
mAb
Lu
OSCC
177
TROP-2
mAb
Lu
Prostate cancer
177
GPA33
mAb
Lu/86Y
Colorectal cancer
211
NaPi2b
F(ab’)2
At
Ovarian cancer
177
PSMA
mAb
Lu
Prostate cancer
212/213
HER2
mAb
Bi
Colon adenocarcinoma
177
HER2
Affibody
Lu
Ovarian carcinoma
212
HER2
mAb
Pb
Colon adenocarcinoma
131
CD138
mAb
I
Breast carcinoma
227
HER2
mAb
Th
Breast carcinoma
131
FR
F(ab’)2
I
Ovarian cancer
177
EGFR
mAb
Lu
Epidermoid carcinoma
177
MUC1
mAb
Lu
Breast carcinoma
177
HER2
mAb
Lu
Breast carcinoma
111
PD-L1
mAb
In
Breast carcinoma
177
111
HER2/EGF bsRICs bsRICs
Lu/ In
Breast carcinoma
213
EGFR
mAb
Bi
Bladder carcinoma
177
L1CAM
mAb
Lu
Ovarian cancer
90
ROBO1
mAb
Y
Small cell lung cancer
90
TfR
mAb
Y
Pancreatic cancer
177
Lewis Y
mAb
Lu
Colon carcinoma
In this project SAS1B receptor was the image target using radiolabeled anti-SAS1B as will be
discribed in more details in following chapters.
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CHAPTER 4: APPROACH AND METHODS
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4.1 Introduction.
A number of monoclonal antibodies (Anti-SAS1B) have been produced including SB2, SB3,
SB4, and SB5 and according to UVA studies, most of these antibodies were identical [121].
Therefore, SB2 and SB5 were selected for labeling with radioisotopes and near infrared dye and
then investigated in vitro and in vivo studies. Among a number of radioisotopes and based on their
physical and chemical properties, 89Zr and

67

Cu were selected to radiolabel anti-SAS1B antibodies

for in vivo imaging and ex vivo biodistribution studies.89Zr possess favorable characteristics
antibody-based for PET imaging [122], [123]. In addition, the production of 89Zr was carried out inhouse at VCU.

67

Cu emits gamma radiation which can be used for Single-Photon Emission

Computed Tomography (SPECT) [124]. Also,67Cu it is one of the best suited isotopes for
radioimmunotherapy because its half-life is long enough to allow good biodistribution within the
tumor [125]. These radionuclides require bifunctional chelators to obtain the best labeling with
antibodies [126]. Bifunctional chelators are capable of coordinating a metal ion and can also be
attached to the antibody [127] . Each radionuclide has its favorable chelators which can form a
complex and reduce detachment of radioisotope [128]. Labeling anti-SAS1B antibodies done
indirectly through two steps including optimization of antibody to the chelator conjugation and
labeling with radionuclide to form a complex with the chelator. Labeling antibodies is challenging
because there are many factors that need to be addressed during conjugation and labeling including
the optimal ratio between chelator and antibody, reaction solution, pH, temperature and time of the
reaction [90].
The other imaging agent used for an optical imaging was near infra-red dye (IR800CW). IR800CW
dye is one of the main dyes used for fluorescence imaging [129]. Near infra-red dyes provide deeptissue and real-time fluorescence imaging [130]. IR800CW linked to NHS-ester group which bind to
antibody directly through amid group and the excess of dye could be removed using size exclusion
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column. Optimizing the molar ratio of dye-to-antibody is important to determine the best ratio of
anti-SASB1 to dye and used for in vitro and in vivo experiments. Among anti-SAS1B antibodies,
(SB5) was selected for radiolabeling with

89

Zr and (SB2) was labeled with

67

Cu and NIRdye

800CW as described below.

4.2 Synthesis of Non-radiolabeled and 89Zr Radiolabeled anti-SAS1B (SB5).
Anti-SAS1B (SB5) was labeled with

89

Zr indirectly through DFO-NCS linker (Chelator)

through two steps. First, SB5-DFO cold conjugation was optimized and then labeled with 89Zr. 89Zr
readily available from our in- house cyclotron.

89

Zr exists as large ion and +4 cation in aqueous

solution, and can be classified as a hard cation [131], so it exhibits a preference for ligands bearing
up to six hard, anionic oxygen donors with chelators such as Desferrioxamine B (DFO) [132].
Desferrioxamine B was selected for this study because it is currently the best available ligand for
Zirconium chelation and its use has been demonstrated in a number of preclinical and clinical
studies [133]. DFO is a bacterial siderophore bearing 3 oxime groups. Computational studies
strongly suggest that DFO forms a hexacoordinate complex with Zr4+ in which the metal center is
coordinated to the three neutral and three anionic oxygen donors of the ligand as well as two
exogenous water ligands as shown in Figure 12.

Figure 12.Coordination complex of [89Zr]- DFO chelation. Adapted from ref [134].
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4.2.1 SB5 Conjugation
The conjugation reaction schematic is depicted in scheme 5. Fifty µg of SB5 was added to
500μl of PBS (phosphate buffered saline solution) and the pH was adjusted to 8.8-9.0 using 0.1M
sodium bicarbonate. DFO solution was prepared by weighting 0.2 mg added to 150 µl of DMSO to
make 1.5 mg/ml solution. From DFO solution, 20μL was taken and added to SB5 mAb solution.
The mixture was incubated at 37°C and mixed a rotating speed of 300 rpm for 60 minutes.

Scheme 5 Reaction Schematic of DFO to SB5 Conjugation.

4.2.1.2 SB5-DFO Characterization.
The conjugation yield of SB5-DFO was monitored using HPLC-UV (High-performance liquid
chromatography and ultraviolet detector) with size exclusion column (SEC) (Superdex 200 10/300
column GE Healthcare, Piscataway, NJ USA) at room temperature. 0.01 M phosphate buffer and
0.14 M NaCl, pH 7.4 were used as mobile phase at flow rate of 0.5 mL min. UV detection was
accomplished at 280 nm using a Waters 2489 UV (10-mm, 11-µL analytical flow cell).
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4.2.2 Radiolabeling SB5 with 89Zr.
Zirconium-89 was produced in the cyclotron using the 89Y (p, n) 89Zr reaction using 13 MeV
incident proton energy. Following radiochemical processing,

89

Zr was obtained in the form of

Zirconium-oxalate solution. [89Zr]-oxalate (4.2 mCi/500uL) solution was neutralized with 200uL of
2M Na2CO3. 15uL of [89Zr] - oxalate solution was added to SB5-DFO conjugation solution and
incubated for 30 minutes. Radiolabeling reaction schematic is shown in scheme 6.

Scheme 6 Reaction Schematic of radiolabeling of SB5-DFO with 89Zr ([89Zr]-DFO-SB5).

4.2.2.1 89Zr-DFO-SB5 Characterization
The reaction yield was monitored by radio-HPLC. Radio detector was connected to UVHPLC to detect the radio activity signal of labeled antibody. This one of the methods used to
determine the radiochemical purity of radiolabeled antibodies. Radiochemical species can be
separated according to the molecular size and weight, and the peak of radiolabeled antibody will
correspond to the peak in UV-HPLC. The [89Zr]-DFO-SB5 solution (20ul) was loaded on RadioHPLC from waters using size exclusion column (SEC) (Superdex 200 10/300 column GE
Healthcare, Piscataway, NJ USA) and the radio detector was connected to the HPLC is Bioscan,
INC, model BFC-3300.The mobile phase was 0.1 M phosphate buffer and 0.14 M NaCl2, pH 7.4, at
a flow rate of 0.5 mL min.
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4.2.2.1.2 Radio-TLC. Thin-layer Chromatography
The radiolabeled SB5 [89Zr]-DFO-SB5 was also monitored by radio-TLC. Thin-layer
chromatography was performed on TLC plates (silica gel plates [Sigma-Aldrich,St. Louis, MO]).
TLC plates at heights 10cm approximately 1ul of the final solution were spotted at the center of the
2 cm mark from the bottom. The spot was allowed to dry for 5 to 10 minutes. The plates were then
placed into a TLC jar filled to about 1cm from the bottom with 10% ammonium acetate and
methanol (1:1) as a mobile phase, and allowed to develop to the 7 cm line from the bottom (about 15
minutes). In this system radiolabeled antibody remains at the origin, while free [89Zr] migrate to the
solvent front. Also, Size exclusion column PD10 was used to purify [89Zr]-DFO-SB5. Using this
column allowed to sort out all labeled antibody from other radioactive components by collecting
small fractions of the reaction solution and determine the radioactivity using TLC.

4.2.3 In vitro study of [89Zr]-DFO-SB5
4.2.3.1 Cell lines and Cell Culture.
SNU539 (Seoul National University) cell lines have been cultured to use them as expressed
target for in vitro and in vivo study. SNU539 cell lines were established from Korean cancer patients
since 1982 and reported in many SNU cancer cell lines, SNU539 was characterized and reported in
uterine tumor tissue (56). SNU539 Cell lines were grown and maintained in RPMI1640
supplemented with 10% heat inactivated fetal bovine serum (Hyclone,Logan,UT), 2mM Lglutamine (2mmol/L), 100 ug/ml

streptomycin (Sigma, St. Louis MO). 10 mM HEPES in a

humidified, 5% CO2 incubator at 37°C. Every other day cells were checked and medium replaced.
When cells growth covers about 70% of the flask, cells detached using accuatase enzyme. Then,
cells were collected, counted and regrow again. When the number of cells reached the required
number for experiments, all cells were harvested.
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4.2.3.2 Cell Uptake
SNU539 cells were cultured and different concentrations prepared 4x106, 2x106 and 0.5x106
for cell uptake of [89Zr]-DFO-SB5. Cells were incubated at 37°C for 2 hours with the same amount
of radioactivity [89Zr]-DFO-SB5. After 2 hours, all cells were washed using PBS and spun for 5
minutes at 1000 rpm. After spun all tubes, supernatant was removed and replaced with PBS. The
radioactivity of participation cell pellets and supernatants were measured using gamma counter. The
uptake of cell was calculated and presence of radioactivity of cells reflects the binding of
radiolabeled SB5 to SAS1B antigens on cell surface.

4.2.4 In vivo imaging of SAS1 Targeting by [89Zr]-DFO-SB5.
4.2.4.1 Animals
Animal experiments were performed according to the policies and guidelines of the Animal
Care and Use Committee (IACUC) at Virginia Commonwealth University. Female nude mice 3
weeks old, obtained from the National Cancer Institute in Bethesda, MD, were caged in groups of
five or fewer, and provided with food and water ad libitum. All animal experiments were performed
for this study in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines
and approved protocol at Virginia Commonwealth University.

4.2.4.2 Mouse Tumor Model
SNU539 cells were inoculated subcutaneously into mice flanks to implant xenograft tumors.
About (5 × 106) of SNU cells in 130ul of phosphate buffer mixed with 30% matrix gel was injected
in each mouse. The tumor growth was monitored using a caliper. When the tumor size reached
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about 1mm in diameter and the volume less than 2000mm3 (Tumor volume calculated using this
formula V= W*2*L/2 [135]) animal were used for in vivo imaging and biodistribution study.

4.2.4.3 PET/CT Imaging
[89Zr]-immuno-PET is a quantitative technique to measure the uptake of radiolabeled
antibody in tumor-associated antigens and the distribution in other organs. A female nude mouse
was injected via tail vain with 247µCi of [89Zr]-DFO-SB5. After intervals of 2 hours, 24 hours, and
72 hours, the mouse was anesthetized by 1% to 2% isoflurane inhalation anesthesia, then positioned
in PET/CT system and images were obtained. The region-of-interest (ROI) was analyzed with the
percent injected dose/gram of tissue (%ID/g). The animal was imaged by both PET and CT. CT
image provided anatomical background for distribution of the radioactivity. Figure 13 shows in vivo
experiments flow work.

Inoculating cancer cells

Xenograft tumor mouse model

Injecting Radiolabeled mAb

PET at 2, 24 and 72

Figure 13. In vivo flow work.

4.2.4.4 Ex Vivo Biodistribution
The biodistribution of [89Zr]-DFO-SB5 in animals was determined by organ following
injection and animal sacrifice. Five nude mice bearing SNU539 tumor xenografts were divided in
two groups. The first group of 3 mice were injected with a solution of [89Zr]-DFO-SB5. The other
groups of 3 mice were injected with the non-specific labeled antibody [89Zr]-DFO-3A4 (as negative
53

54

control) via the tail vein. After 24 hours, one of the mice died. All other mice were sacrificed, blood
and tissues were collected from each animal and weighed, and radioactivity of 89Zr in each sample
was determined by gamma-counting on a Perkin Elmer Wallac Wizard 1470. The radioactivity
percent of injected dose per gram %ID/g of each organ was calculated using all data, including
activity of injected solution (Standard), organs weighed and measured activity of each organ.
The collected organs were blood, heart, lung, liver, gallbladder, spleen, kidney, tumor, femur, and
muscle.

4.3 Radiolabeling SB2 with Copper-67 (67Cu)
In addition to Zirconium-89 (89Zr), radiolabeling of SB2 was also investigated using another
radionuclide, Copper-67 (67Cu).

67

Cu is an attractive theranostic radionuclide because its decay

results in the emission of both therapeutic (beta particles) and imaging (gamma-rays) radiation. It
emits beta particles with a mean energy of 141 keV and three gamma rays (91, 93 and 182 keV)
suitable for SPECT imaging [124]. Additionally, the half-life of 67Cu is 62 h is well suited to the bio
kinetics of antibodies [136]. Additional advantages to these favorable physical characteristics of
67

Cu are the availability of copper chelators with high in vivo stability [136], [137]. In this study the

chelator p-SCN-Bn- DOTA (S-2-(4-Isothiocyanatobenzyl)-1, 4, 7, 10-tetraazacyclododecane tetra
acetic acid) was selected to link

67

Cu to SB2. It is an attractive candidate for conjugation of

radioisotopes to antibodies [138]. In general, macrocycles, like DOTA form complexes that are
essentially irreversible under physiological conditions and demonstrate higher thermodynamic
stability than linear chelators, such as DTPA [139] (Figure 14).
In order to determine the optimum molar ratio of DOTA: SB2, experiments were carried out
to determine best ratio for radio-labeling.
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Figure 14. Structure of [67Cu]-DOTA complex adapted from reference [123].

4.3.1 Optimizing SB2-DOTA Conjugation
Determining the molar ratio of chelator binding to antibody is an important factor for
optimized radiolabeling. Chelators bind to amino acids on the antibody through the functional group
of the chelator. The p-Isothiocyanatobenzyl DOTA is one of the favored bifunctional chelators for
labeling antibody with copper radioisotope. It forms hermodynamically very stable complexes with
copper through the coordination chemistry[123], [136]. DOTA is water-soluble and reacts easily in
slightly basic solutions (pH 8–9) with lysine side chains which is one of the most common residues
on antibody surfaces [140].
DOTA-SB2 Conjugation was optimized by preparation of multiple molar ratios of SB2DOTA conjugation (1:3, 1:5, 1:7 and 1:10) and incubated at 37C for 24 hours. The conjugation
yield was determined by UV-HPLC using size exclusion column (Phenomenex Yarra SEC 2000
150x 4.6mm) and mobile phase of 0. 1M Sodium phosphate buffer pH 6.8 with flow rate was 0.35
ml/min with. The conjugation was monitored for one week at different time points (0, 1, 2, 4, 6, 8,
10 and 24 hours) by injecting 20ul from conjugation solution into the HPLC.
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4.3.2 Radiolabeling SB2. [67Cu]-DOTA-SB2
Based on the successful optimization of SB2-DOTA conjugation,

67

Cu was then used for

radiolabeling. Cold conjugation of SB2-DOTA at 1:5 ratio was prepared in solution volume of
200ul of potassium phosphate buffer, and the pH was adjusted between (8 -9) using 0.1M of sodium
bicarbonate. 10ul (362uCi) of [67CuCl2], in 0.1M HCl (pH=5.0-5.5) was added to SB2-DOTA (pH=
8-9) solution and the pH was adjusted to about 6- 6.5, using 0.1M HCL. The reaction was incubated
37°C for 30 minutes. Radiolabeling efficiency and radiochemical purity of [67Cu] -DOTA- SB2 was
determined by radio-TLC using 10% (w/v) ammonium acetate: methanol (1:1) as the mobile phase.
In this system, radiometal-labeled antibody [67Cu] -DOTA- SB2 remains at the origin, while DOTA[67Cu] or free 67Cu will migrate to the solvent front on ITLC plates.

4.3.2.1 Purification with PD10
ITLC showed high labeling yield of SB2 antibody [67Cu] -SB2-DOTA and some of [67Cu]DOTA-or 67Cu. In this case, Size exclusion column PD10 was used to purify labeled antibody from
other species.

4.3.3 In Vitro Evaluation
4.3.3.1 Cell Uptake
SNU539 uterine cancer cell line and SK-OV3 human ovarian cancer cell lines were used for
study. Both cell lines were grown at 37°C and were maintained until cell count reached about 50
million. In triplicate, vials with 1 million cells in 1m of growth medium were prepared, and 100μl
of [67Cu]-DOTA-SB2 solution was added to each vails. All vials were incubated at 37°C for 4
hours, followed by spinning at 1000 rpm for 5 minutes. Then, supernatant was collected, and the cell
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pellets were washed three times with PBS. The radioactivity of all samples, cell pellets, supernatant,
and wash tubes were measured by gamma counter and the uptake for both cell lines was calculated.

4.3.4 Ex Vivo Evaluation
Animal experiments were performed according to the policies and guidelines of the Animal
Care and Use Committee (IACUC) at Virginia Commonwealth University. Biodistribution studies
67

of both

CuCl2 and [67Cu] - DOTA were performed ex vivo on 12 female nude mice. After these

mice were divided into two groups, one group was injected with 67Cu and the other group injected
with [67Cu] - DOTA. The biodistribution for these two compounds were measured after 1 and 6
hours as described below.

4.3.4.1 DOTA-[67Cu] Biodistribution
Six mice were injected via tail with 200ul of [67Cu]-DOTA (2μCi) solution and divided into
two groups. Biodistribution was determined in the first group after 1 hour and the other group after
6 hours (n=3). Therefore, the first group of mice was dissected after 1 hour (n=3), and the second
group was dissected after 6 hours (n=3). All organs were collected to measure the radioactivity of
[67Cu]-DOTA in each tissue by gamma counter. Data showed rapid clearance of [67Cu]-DOTA from
the kidney after 6 hours while slow in blood, liver, and spleen, (Figure 20). Also, there was no
uptake of [67Cu]-DOTA by the brain and less uptake in bones and muscles.

4.3.4.2

67

CuCl2 Biodistribution

Similarly, 67Cu (4uCi) 200ul volume was injected via tail in triplicate mice. The first group
of mice was dissected after 1 hour and the other group dissected after 6 hours. All organs were
collected, and 67Cu activity in all organs was determined by gamma counter.
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4.4

Labeling SB2 with NIRdye800CW
NIR dye 800CW is one of the most used dyes for fluorescence image-guided surgery [141].

It has less interaction with serum proteins and, when injected intravenously, cleared through the
kidney with some uptake in the liver [142]. The most commonly applied strategy for labeling
antibodies by using the activated group N-hydroxysuccinimide (NHS)-ester to form covalent bond
between primary amines of the antibody and carboxylic acid of (NHS)-ester [143] (Figure 15). This
conjugate to N-terminus of lysine residues which is the most abundancy and accessible amino acids
in antibodies. As a result, having this could lead to many fluorophores per targeting antibody and
cause self-quenching, which will reduce brightness and also, when the fluorophores are conjugated
in or close to the antigen-binding region, could impact the binding capacity [144]. Therefore,
optimizing the conjugation of antibody with NIR dye 800CW is important to determine the degree
of labeling that can give high fluorescence signal in vivo with less background.

Figure 15. NIR dye 800CW NHS-ester structure and absorption and emission spectra.
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4.4.1 Optimizing the Conjugation of Monoclonal Antibody to IRdye800CW
Conjugation of monoclonal antibody SB2 (155 kDa) with NHS-IRDye800CW from LI-COR
Biosciences (absorption/Emission: 774/789nm) was optimized by following LI-COR conjugation
protocol. The stock solution was prepared by dissolving 0.1mg dye with 25ul of ultra-pure water
and mixed thoroughly. The antibody solution was prepared by adding 50ug (0.33nmol) of SB2 to
125ul of phosphate buffer. The antibody was combined with reconstituted reactive dye at different
molar ratio 1:1, 1:2, 1:3 and analyzed to determine the optimal conjugation ratio. IR800CW dye
was added to SB2 solution and the pH was adjusted between 8.3 - 8.5 using 1M of potassium
phosphate buffer K2HPO4 , pH 9. The reaction solution was incubated at 20°C -25°C for 2 hours.
The excess amount of free dye was removed using Zeba desalting column (Thermo Fisher
Scientific) after equilibrated with 50mM phosphate buffer, pH 8.5. The conjugation yield was
determined using UV/Vis systems.

Scheme 7 Labeling SB2 with IR800CW.

4.4.2 In Vitro Evaluation
4.4.2.1 Cell Culture
SNU539 Cell lines grown in RPMI1640 were supplemented with 10% fetal bovine serum,
glutamine (2 mmol/L), penicillin (100 unit/ml), HEPES and maintained in a humidified, 5% CO2
incubator at 37°C. When cells reach about 70% of growth in the flask, cells detached using accutase
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enzyme and collected. Then cells viability checked using trypan blue and counted. All cells
harvested when reach the number needed for in vitro experiments.

4.2.2 Cell Binding
Both SNU539 and SK-OV3 express SAS1B, but A549, a lung cancer cell line does not
express SAS1B. About 0.1x106 of each cell line were grown in 6 plate wells for 24 hours at 37°C.
After 24 hours cell growth, the media was discarded and cells incubated with SB2 labeled with NIR
dye 800CW solution at 37°C for 1 hour. Another 6 well plate with the same cells was incubated
with IgG labeled with NIRdye800CW for 1hour. All cells were washed using phosphate buffer and
examined by fluoresce microscope.

4.5 Statistical Analysis
The significant differences in the ex vivo and in vivo studies were determined using the equal
variance analysis (ANOVA) (JMP software), or Student’s t-test. P value of <0.05 was considered as
statistically significant difference. The data shown in graphs are mean SEM.
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CHAPTER 5: RESULTS
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5.1 Radiolabeling SB5 with 89Zr
5.1.2 SB5 Conjugation
High-performance liquid chromatography (HPLC) results showed high reaction yield of
DFO–SB5 cold conjugation (Figure 16). The peak of SB5 was at 24 minutes retention time. The
small peak at retention time 37.12 represent DFO. The area under the peak represents the
conjugation yield of DFO to SB5. As the HPLC chromatograph show, about 92% of DFO was
conjugated to SB5.

UV

SB5-DFO

Figure 16. Conjugation of anti-SAS1B (SB5) to DFO (SB5-DFO), 20ul of conjugation reaction was
injected into HPLC. The chromatogram shows 92% conjugation yield. The retention time of (SB5)
mAb was 24.1 minutes and DFO retention time was 37.2 minutes.

5.1.3 SB5 Radiolabeling
5.1.3.1 Radio-HPLC Chromatography
Radio-HPLC was used to determine the radiolabeling yield of SB5 and the radioactive signal
should match the UV-HPLC SB5 signal if the

87

Zr label SB5. The radio-HPLC chromatograph

showed that the majority 66.96% of radioactive signal matches the UV signal of SB2. There were
also multiple small peaks which could be SB5 fragments (Figure 17).

Figure 17. Radio HPLC shows radiolabeled SB5 ([89Z]-DFO-SB5). Also, it shows also small peaks
which could be radiolabeled SB5 fragments.
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5.1.3.2 Radioactive Instant Thin-layer Chromatography.
(Radio-ITLC of [89Zr-DFO-SB5]
The radio-instant thin layer of chromatography showed high radioactive signal of labeled
SB5 with very small signal representing free 89Zr or [89Zr]-DFO (Figure 18).

Figure 18. Radio-TLC of [89Zr] - DFO-SB5 showing quantitative radiolabeling yield.

5.1.4 In Vitro Study Results
5.1.4.1 Cell Uptake
The radioactivity of participation cell pellet was measured using gamma counter. The
presence of radioactivity of cells reflects the binding of radiolabeled SB5 to SAS1B antigens on cell
surface. Results showed the radioactivity decreased by decreasing the cell concentration (Figure 19).
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Figure 19. Radioactivity of different SNU539 cell concentrations after incubated for 2 hours at 37°C
with Same amount of [89Zr]-DFO-SB5 radioactivity.

5.1.5 In Vivo Imaging of SAS1B Targeting
5.1.5.1 Tumor Growth Monitoring
After injecting 5x106 of SNU539 cells subcutaneous into mice flank to implement the
xenograft tumor, the mice were monitored for tumor growth. At week 4, the tumors started
appearing and a clipper was used to take measurements of the length and width of the tumors.
In most of the mice, tumor size took about 6-8 weeks to reach 1mm in diameter (Figure 20).

Figure 20. Monitoring Tumor growth.
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5.5.2 PET/CT Imaging
The animal was imaged by both PET and CT.

The CT image provided anatomical

background for distribution of the radioactivity (Figures 21 and 22). As the image showed, the vast
majority of radioactivity is following clearing from the blood, spleen, and liver, as well as other
organs. The second observation is the right flank of the tumor showing uptake, while the left flank
did not show any uptake. This uptake is because of SAS1B binding Labeled SB5. Also, more
activity was noticed in the bone and this is more likely due to the detachment of 89Zr from DFO and
uptake by the bone.

Figure 21. Whole female nude mouse bearing xenograft tumor injected with [89Zr]-DFO-SB5 and
imaged via PET/CT show the Maximum Intensity Projection 72 hours post injection. Low
accumulation of [89Zr]-DFO-SB5 in the tumor while high uptake in bone, liver, and spleen.
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Figure 22. PET /CT coronal and sagittal images, across tumor area, taken at 2 hours, 24 hours, and
72 hours post inj. Region of interest (ROI) results showed average of less than 1% of activity shown
in the tumor while more uptake in bone, spleen, and liver.

5.1.5.3 Ex Vivo Biodistribution
After 24 hours, biodistribution results showed that about 6% of radioactivity is in the blood
and the major distribution is in the liver, spleen, and kidney (Figure 25). Also, an interesting
observation is the non-specific antibody 3A4 (negative control antibody) is showing significantly
lower uptake, although the specific antibody SB5 did not show significant tumor uptake (less 1%).
Even though both antibodies were chelated by DFO, results showed more

89

Zr detachment from

SB5 than 3A4 by looking to uptake of the most organs (Figure 23).
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Figure 23. Ex vivo results of [89Zr]-DFO-SB5 and [89Zr]-DFO-3A4 biodistribution in two groups of
mice after 24 hours. Data shows an average of less than 1% tumor uptake in mice injected with
[89Zr]-DFO-SB5 (Green) while high uptake in blood, liver, and spleen compared to kidney.
Nonspecific labeled antibody [89Zr]-DFO-3A4 (blue) showed very less uptake by tumor, and similar
or less uptake in heart, lungs, kidneys, and blood.

5.1.6 Discussion
Cold conjugation of anti-SAS1B (SB5) with the chelator DFO was performed before
labeling with

89

Zr according to published protocol [145]. The results showed greater than 90% of

conjugation yield in most of SB5 and DFO conjugation. HPLC with size exclusion column was used
to evaluate the cold conjugation yield [146] [147]. Firstly, anti-SAS1B and the chelator separately
were injected into the HPLC to identify the retention time of each one, based on their molecular
weight. Since antibody has higher molecular weight than the chelator, antibody retention time was
24 minutes, which is less than the retention time of the chelator DFO was at 37 minutes as shown in
Figure 7. When the cold conjugation injected, the HPLC chromatograph showed two peaks. The
area under the peaks represents the amount of antibody and the chelator in the conjugation reaction.
Therefore, HPLC was used for quantitatively monitor the conjugation yield. If complete conjugation
is achieved, we will see only one peak at the retention time of antibody. However, when both the
antibody and chelate peaks are detected in the chromatogram, this indicates that the conjugation
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reaction did not go to completion and the area under the peaks reflects the degree of conjugation
efficiency.
Once reaction parameters are optimized and validated by radio-HPLC, a second
chromatographic method was used, namely radio-TLC. This offers a simple and quick method based
on the migration of radiolabeled antibody versus the migration of non-antibody radioactivity on the
TLC plate. This method was adopted for rapid evaluation once being validated by radio-HPLC. On
the radio-TLC plate, the radiolabeled antibody will stay at the origin while non-antibody radioactive
species will migrate to solvent front. This is done by scanning the entire plate using a faster
radiation detection. Labeled SB5 [89Zr] –DFO-SB5 was evaluated using thin layer chromatograph
TLC and the chromatograph showed about 80% of SB5 was labeled with

89

Zr. Following the

successful radiolabeling of SB5 and SB2 with different yields, the radiolabeled antibody needs to be
purified from any non-antibody radioactivity. This has been accomplished by using PD10 desalting
columns containing sephadex G-25 resin for rapid buffer exchange, desalting, and removal of small
contaminants, including salts and radioactive labels. In this system, radiolabeled antibodies elute in
the first few eluted fractions, while non-antibody radioactivity elutes in later fractions. Collected
fractions are re-analyzed to confirm purity.
Purified [89Zr]-DFO-SB5 was used for in vitro and in vivo experiments. Cell uptake study
using radiolabeled [89Zr]-DFO-SB5 and SNU539 cells showed that the amount of radiolabeled
antibody taken up by the cells increases with increasing cell concentration. The level of radioactivity
used ranged from micro curies for in vitro experiments to mille-curie levels for ex vivo and in vivo
work [148]. For example, longitudinal imaging of the same animal and prolonged biodistribution
studies usually require larger amounts of radioactivity to be injected in order to detect it days and
weeks later, depending on the half-life of the radionuclides[149]. Moreover, one also needs to
account for some radioactivity that may be lost due to retention in syringes, vials, and other
68

69

materials encountered by the radioactivity [150]. In addition, the amount of radioactivity used need
not be so high as to cause an effect on the antibody itself [151]. This is why the immunoreactive
fraction of the antibody needs to be determined at different levels of radioactivity. Retention of
immunoreactivity is also desirable following radiolabeling, as a low immunoreactive fraction could
compromise binding of the antibody to its target protein SAS1B.
PET/CT images of [89Zr]-DFO-SB5 uptake in general reflect the biodistribution profile,
including some uptake in tumor (Figures 21 and 22).

The bone uptake is indicative of

89

Zr

detaching from the radio-conjugate and accumulating in bone. This observation has been reported
in other studies [152] [153] [154]. The overall biodistribution of [89Zr]-DFO-SB5 (specific for
SAS1B) and [89Zr]-DFO-3A4 (presumed to be non-specific for SAS1B) is similar across a number
of tissues including blood. The SNU tumor uptake was slightly higher for [89Zr]-DFO-SB5 than that
for [89Zr]-DFO-3A4, although the significance of this difference was not determined. It has been
shown by western blot that SNU cells express more SAS1B antigen on their surface compared to
3A4 SAS1B expression level [155]. It is also worth noting that the uptake of [89Zr]-DFO-3A4 is 2-3
times higher than that of [89Zr]-DFO-SB5 in both liver and spleen at 24 hours post injection.

69

70

5.2 Radiolabeling SB2 with Copper-67 (67Cu)
5.2.1 Optimizing SB2 & DOTA Conjugation
The choreographs of HPLC for the different ratios SB2-DOTA conjugation showed the
highest yield of conjugation for both ratios 1:3 and 1:5, which were >95%% after 24 hours (Figure
24). HPLC chromatograph (Figure 25) shows SB2-DOTA peaks at the beginning of the reaction
(Figure 25A) and after 24 hours (Figure 25B).

Chromatograph shows the peak of DOTA is

completely disappeared and the area under the peak of SB2 was increased, illustrating the complete
conjugation of DOTA to SB2.

Figure 24. Optimizing SB2& DOTA conjugation, different ratio SB2 & DOTA (1:3, 1:5, 1:10)
Conjugation yield was measured at 0,2,4,6,8,10 and 12 hour time points during 24 hours by 20ul
from conjugation solution into HPLC.
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A

B

Figure 25.HPLC profile of SB2-DOTA conjugation ratio 1:5. 20ul of SB2-DOTA conjugation
solution was injected into HPLC. (A) HPLC profile after 30 minutes of reaction. (B) HPLC profile
after 24 hours of reaction. Almost 100 % of DOTA was conjugated to SB2 monoclonal antibody
after 24 hours of reaction at 37°C.

SB2-DOTA Stability
Conjugation of SB2 with DOTA was stored at 4°C and monitored for one week. The results
showed that SB2-DOTA conjugation was stable and the conjugation yield was above 90%
(Figure 26).

Stability of SB2-DOTA Conugation
120

Area %

100
80
60
40
20
0

0

20

40

60

80

100

120

140

160

180

Hours
1:03

1:05

1:10

Figure 26 .Stability of SB2-DOTA was monitored for one week using HPLC. At each time point
20ul of SB2-DOTA solution was injected into the HPLC. The HPLC chromatogram showed SB2DOTA conjugation remains stable for one week at 4°C.
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5.2.2 Radiolabeling
Radio-TLC results showed >85% radiolabeling efficiency (Figure 27). Also, there is a small
peak which represents free

67

Cu or DOTA-[67Cu] or both together. Therefore, this is required

purification.

Figure 27. TLC result of [67Cu] –DOTA-SB2. 1μl of [67Cu] –DOTA-SB2 solution was spotted in
TLC plates and scanned by gamma counter with the appropriate energy window to detect the
labeling yield, which was > 85% of labeled SB2 ([67Cu] -DOTA- SB2).

5.2.2.1 Purification with PD10.
PD10 was used to purify labeled antibody from other species. Figure 28 shows the
purification result which was greater than 95% of [67Cu] -DOTA-SSB2.

Figure 28. TLC results of purified [67Cu] -DOTA- SB2 by PD10 column.
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5.2.3 In vitro Evaluation
5.2.3.1 Cell Uptake
Results showed significant uptake of [67Cu]-DOTA-SB2 by both SNU539 and SK-OV3 cell
lines p < 0.05, while low uptake of [67Cu]-DOTA and free

67

Cu (without antibody). The same

radioactivity was used (4uCi) and all cell were washed very well using PBS.

The result of

radioactivity level associated with the cells confirmed specific binding of labeled SB2 to SAS1B
surface antigen. (Figure 29).

Figure 29. Results showed that labeled antiSAS1B (SB2) significantly targeted uterine cell lines
SNU539 and ovarian cell lines SK-OV3 compared with [67Cu]-DOTA or free [67Cu]. SK-OV3
ovarian cell lines also express SAS1B antigens (24). Further experimentation is required to compare
the uptake of SNU539 with different cell lines that do not express SAS1B.

5.2.3.1 DOTA-[67Cu] Biodistribution
Biodistribution of radioactivity data in each organ was collected with high radioactivity after
one hour in kidney, spleen, liver, and lung. It also showed rapid clearance of [67Cu]-DOTA from
kidney after 6 hours while slow in blood, liver, and spleen (Figure 30). There was no uptake of
[67Cu]-DOTA by the brain and less uptake in bones and muscles.
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Figure 30. Gamma counter results show the uptake of [67Cu]-DOTA in different body organs after
1 hour and 6 hours.

5.2.3.2 Copper 67 (67CuCl2) Biodistribution
As seen in results of 67CuCl2 Biodistribution shown in Figure 31, most of the

67

Cu activity

was cleared by kidney after 6 hours and the activity in urine sample supports that too. Also, almost
no uptake by the brain and less uptake in the bone. Liver, heart, and blood still showing activity
after 6 hours. This indicates that some of the 67Cu might bind to some of blood proteins and is still
circulating in the blood.
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Figure 31. In vivo Copper67 (67CuCl2) Biodistribution. Results showed rapid clearance of 67CuCl2
from kidney, lung, spleen and urine after 6 hours, while still more uptake in blood, heart and liver
after 6 hours compared to 1hour uptake.

5.2.4 Discussion
Optimization of antibody to chelator was performed first for SB2 with DOTA to maximize
conjugation yield and radiolabeling to obtain high radiochemical yield [156] [157].

For SB2-

DOTA conjugation, two parameters were studied, the molar ratio of mAb to chelator/linker and the
time of conjugation reaction. Three different ratios, 1:3, 1:5, and 1:10, were investigated for
conjugation yield using HPLC at different times of conjugation reaction. The molar ratios (antibody:
Chelator) of 1:3 and 1:5 were found to yield optimum conjugations after reacting the chelate and
antibody for 24 hours at 37°C.
The molar ratios of 1:3 and 1:5 were adopted for subsequent radiolabeling experiments.
Anti-SAS1B antibody SB2 was radiolabeled with different levels radioactivity of 67Cu radionuclide.
There was less uptake of [67Cu]-DOTA and free

67

CuCl2 in SNU539 cells than that of the

radiolabeled antibody SB2-DOTA-[67Cu] t-test =0.0108 and 0.0039, indicating that at least part of
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the higher uptake of the radiolabeled SB2 is due to binding of SB2 antibody to its SAS1B target.
Correlation between radiolabeled uptake and SAS1B expression would be useful to show binding
specificity.
The biodistribution of both [67Cu]-DOTA and free [67Cu]-Cl2 were also determined.
Compared to antibody, these are small molecules and are cleared rapidly from the blood with
subsequent clearance by kidney and, to some extent, by hepatobiliary excretion. This could be due
to the slow [67Cu]-DOTA metabolism in liver [158].
Free 67Cu biodistribution also showed fast clearance by the kidneys after 6 hours, which is
matched by corresponding activity in the urine. Activity in the liver is indicative of copper
metabolism in the liver and also binding to cerepruplasmin, a copper binding protein [159]. Further
experiments with different cells lines do not express SAS1B surface antigen is required to
investigate the significance of radiolabeled SB2 targeting SNU539 cells. As mentioned before, there
are many factors contributing to cell uptake and competeting the binding of antibody to target
antigen. These include, linking the chelator to antibody and the effect of radiation on the nature of
the antibody when it’s labeled with radionuclides.
Ex vivo preliminary experiments were done before in vivo imaging to reveal organ-based uptake.
These also help to guide the in vivo experiments.
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5.3 Labeling SB2 with NIRdye800CW
Near infra-red dye800CW was used to label antiSAS1B SB2 or in vitro experiments.
Therefore, optimizing of antibody to dye (SB2-IR800CW) conjugation was done first to determine
the optimal ratio of conjugation. Then, the optimal conjugation ratio of SB2-to-IR800CW was used
for in vitro work.

5.3.1 SB2-IRdye800CW Conjugation.
Anti-SAS1B (SB2) was conjugated to IR800CW in different molar ratios 1:1, 1:2 and 1:3 and
analyzed using UV/Vis systems. Absorptions and emissions of SB2-IR800CW were determined
(Figure 32A). The absorption and emission spectra of SB2-IRD800CW matches the absorption and
emission spectra of IR800CW dye from Licor (Figure32B). Figure 33 shows the absorption of SB2IR800CW ratio 1:3. The absorption of SB2-IR800CW increases about two-fold from ratio 1:1 to
1:2, whereas, the molar ratio 1:3 of SB2-IR800CW increased to one-fold from ratio 1:2 (Figure 34).

Figure 32-A. Absorption
and emission spectra of SB2 labeled
with NIRDye800CW

Figure 32 B-. Spectra of NIRDye 800C
provided by LICOR
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Figure 33. SB2&IR800CW 1:3 ratio absorption measured usung UV/Vis system.

Figure 34. UV/Vis results of different SB2 & Dye ratios.
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5.3.2 Conjugation Stability
Stabilty of SB2 &IRDye 800CW conjugations in different ratios and the unconjugated dye
IRdye800CW were monitored for a period of 5 days using UV/Vis spectrophotometer. There was
steady slight dercreasing of fluorescent signal over time for both SB2&dye and the unconjugated
dye (Figure 35) . The conjugated SB2 was stored at 4°C with protection from the light during this
time.

Figure 35. Antibody SB2 -IR800CW stabilty. Absorbances of three ratios of SB2-IR800CW (1:1,
1:2 : 1:3) and unconjugated dye 800CW for 5 days.

5.3.3 Cell Binding
Three different cell lines were grown in two 6-well culture plates. Two of these cell lines
were SNU539 and SKOV3 which express SAS1B surface antigen and the other one is A549 cell
lines (lung cell lines) which does not expess SAS1B. These cells were incubated with SB2 labeled
with IR800CW in one 6-well plates for one hour at 37°C and the same type of cells in another 6well plates were incubated with nonspesfic antibody IgG labeled with IR800CWfor one as negative
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control. This followed by washing the cells with saline to remove any unbinded labeled SB2, IgG or
dye.These cells were examined using fluoresence microscpe (Figure 36).
Near infra-red dye signals were seen in SNU539 and SKOV3 cell lines which incubated with SB2IR800CW while no signal was seen from A549 cells. Also, there were no fluorsence signals when
the cells incubated with IgG-IR800CW. This illistrated that there was binding of SB2-IR800CW
with SAS1B surface antgen expresed by SNU539 and SK-OV3.

Cancer cell lines

IgG-IR800CW

SB2-IR800CW

SNU539

SK-OV3

A549
Figure 36.Three different cells, SNU539 uterine cancer cells, SK-OV3 ovarian cancer cell, and
A549 lung cancer cell. These cells were treated with SB2 labeled with IR800CW and IgG labeled
with IR800CW. Both SNU539 and SK-OV are expressing SAS1B but A549 does not express
SAS1B. Therefore, there is uptake of SB2-IR00CW for both SNU539 and SK-OV cell lines,
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5.3.4 Discussion
Near-infrared dye was chosen as an alternative to radioactive agents to labeled anti-SAS1B
(SB2) as an image guide for tumor localization and Biodistribution study. Near infra-red dye
800CW-NHS ester was prepared according to good manufacturing guidelines [160]. Optimization
of antiSAS1B SB2 with IRDye800CW-NHS ester conjugation was performed to obtain the optimal
ratio that could be used in vitro and in vivo and determine high fluoresce signal less background
noise, decrease the effect of antibody-antigen binding, and reduce dye toxicity due to the excess of
dye [161]. Optimization of SB2-IR800CW was done by reacting different molar ratios (antibody:
Dye) 1:1, 1:2 and 1:3 in phosphate –buffered saline (PBS, pH 8.3) solution. The results of UV/Vis
analyzer showed the ratio 1:2 of SB2 to dye conjugation represent a good signal with less
detachment of dye to antibody because when the ratio was increased to 1:3, the intensity increased
just to one-fold by comparing the intensities of 1:1 and 1:2 ratios. The ratio 1:2 of conjugation was
used for in vitro and in vivo studies.
In vitro study was done by determining the fluorescence signals which were produced after
incubating SB2-IR800CW with SNU539 and SK-OV3 cell lines which are expressing SAS1B and
compared to fluorescence signals produced when incubating the same cell lines with nonspecific
antibody IgG labeled with IR800CW. Additionally, different cell lines A549 (cancer cell lines)
were incubated with SB2-IR800CW and IgG-IR800CW. Fluorescence signals were determined
using fluorescence microscope and the results showed some signals were produced from SNU539
and SK-OV3 cells that were incubated with SB2-IR800CW. There were no signals from the same
types of cells incubated with IgG-IR800CW. Moreover, there was no fluorescence signal produced
by A549 cell lines. This confirms that there was specific binding of SB2-IR800CW to SAS1B
surface antigen on SNU539 and SK-OV3 cell lines.
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CHAPTER 6: OVERALL DISSCUSSION
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6.1 Radiolabeling of SB2/5 with 89Zr
In this work, two of anti-SAS1B (SB5 and SB2) were radiolabeled with 89Zr and 67Cu
respectfully. Anti-SAS1B SB2 was also labeled with near-infrared dye 800CW. The labeling of
SB5 and SB2 was performed to investigate the in vitro and in vivo binding of both anti-SAS1B to
uterine cancer surface antigen SAS1B. The over-expression of SAS1B in several types of cancer
cells, including uterine was a novel discovery by the University of Virginia and is an opportunity for
tumor receptor imaging which could guide and improve cancer detection and treatment. Labeling
with 89Zr was preformed based on a substantial number of studies showing promising PET imaging
with 89Zr labeling [162], in addition to 89Zr was available at VCU hospital. 89Zr physical and
chemical properties are attractive, such as 78.8 hours of half-life which matches antibodies’ halflives. Also, 89Zr was classified as a hard cation that binds strongly to the chelator through six hard,
anionic oxygen donors of Desferrioxamine (DFO) [83]. DFO chelator was chosen as a linker
between SB5 and 89Zr because it is the preferred chelator for 89Zr labeling and it binds to antibodies
through the lysine amino acid residues which are available with about 80% on antibodies.

6.2 SB5-DFO Conjugation
In order to label SB5 with 89Zr, firstly SB5-DFO conjugate was optimized through many reactions
with different reaction variables. The optimized conjugation was described in the Methods chapter.
The conjugation yield of optimized reaction was more than 85%. Conjugation of SB5 with DFO was
evaluated using HPLC through a size exclusion column where the qualitative and quantitative yields
of conjugation can be determined. This conjugation yield was encouraging compared with other
studies for 89Zr labeling antibodies. Optimization of antibody conjugation with chelators takes time
because of a number of factors affecting reaction yield and stability. Therefore, radioactive isotope
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could not be ordered unless good optimization was performed because of the decay of radioactive
isotope and it is also expense.

6.3 89Zr-DFO-SB5
Once the conjugations of SB5 with DFO were optimized, 89Zr was ordered for labeling SB5DFO. Different labeling reactions were performed and the optimized procedures resulted in an
average yield of 67±8%. Other studies with 89Zr-DFO antibody labeling reported similar yield after
purifications [163] . The results of HPLC chromatograph showed some fragmentation of SB2. This
might be the effect of radioactivity of 89Zr, and needs to be investigated. In order to remove all
unwanted labeling, the reaction was purified using a size exclusion column PD10. The purified
fractions were analyzed using radio-TLC, and the highest yield of labeling was used for in vitro and
in vivo work.

6.4 SB2 DOTA Conjugation and [67Cu]-DOTA-SB2
Optimizing the conjugation of SB2 with DOTA was performed first. Different ratios of SB2DOTA were investigated in different conditions of incubation temperature, speed of shaking, and
reaction time. The ratios 1:3 and 1:5 showed about 100% of conjugation yield using an HPLC-size
exclusion column. This reaction was incubated at 37C for 24 hours. This conjugation of SB2-DOTA
was monitored for one week and was stable at 4C. The conjugated SB2-DOTA with 1:5 molar ratio
was labeled with 67Cu, in chloride form buffered solution (PH=4-5). Radiolabeling yield reached
85% and following PD10 purification, a radiochemical purity of more than 95% was achieved. This
is comparable to other 67Cu DOTA-Mab studies (refs).

84

85

6.5 Evaluation of radiolabeled SB2 and SB5 in cells expressing SAS1B
All in vitro experiments were done to investigate the binding of SB5-DFO-[89Zr], SB2DOTA- [67Cu] and labeled SB2 with NIR dye 800CW to SAS1B uterine cancer cell surface antigen.
All results showed the specific binding of labeled anti-SAS1B antibodies to its target SAS1B.
SNU539 cells in different numbers were incubated with labeling SB5with 89Zr for 2 hours and then
washed to remove any unbinding species. The radioactivity associated with cells was measured and
the results show the radioactivity increased when the cell number of SNU539 was increased. This
indicates the binding of radiolabeled SB5 to expressed SAS1B on SNU539 cells.
While the in vitro work of radiolabeled SB2 with 67Cu, SB2 was labeled with 4uCi of 67Cu
and incubated with SNU539 and SK-OV3 and similar radioactivity of 67Cucl2 and DOTA-[67Cu]
were also incubated with SNU539 cell line. After washing all cells, the radioactivity measures
showed high uptake of SB2-DOTA-[67Cu] for both SNU539 and SK-OV3 cells compared to the
uptake of 67Cu and DOTA-[67Cu] p value <0.05. Both SNU539 and Sk-OV3 cell line express
SAS1B which indicate the specific binding of radiolabeled SB2 to SAS1B.

6.7 In Vivo imaging and Biodistribution.
After confirming the specific binding of labeled anti-SAS1B antibodies to its target SAS1B,
in vivo and ex vivo work were done to determine tumor uptake and biodistribution. The in vivo
experiments include culturing cell lines, monitoring cell growth, assessing cell viability, and the cell
were harvested and inoculated subcutaneously into the mice flanks to implement a tumor. All these
steps took about 3 months because of the slow growth of SNU539 cell line. When tumor animal
model was prepared for [89Zr]-DFO-SB5 experiments, [89Zr]-DFO-SB5 was injected in a female
mouse bearing tumor and the PET images of the mouse were taken at different periods of time. The
results showed different levels of [89Zr]-DFO-SB5 radioactivity accumulated in different body
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organs. More uptake was shown in bone, liver, and spleen after 72 hours while less uptake by the
tumor. Also, more bone uptake of 89Zr was reported in a number of studies [153]. In addition, high
radioactivity can affect the immunoreactivity. The HPLC chromatogram results also showed small
peaks which might be SB5 fragments due to the effects of radioactivity of 89Zr. The ex vivo results
illustrated the biodistribution of radioactivity in each organ. The ex vivo results were similar the PET
scan results, less uptake by the tumor compared to other organs. In addition, high levels of
radioactivity were determined in the bone, spleen, and liver. Radioactivity of [89Zr]-DFO-SB5
toward SAS1B expressed by uterine tumor was noticeable compared with the uptake of nonspecific
antibody [89Zr]-DFO-3A4.
It is important to know the accumulation profile of radiolabeled components that make up
the radio-conjugate, such as 67CuCl2 and [67Cu]-DOTA. In this regard, ex vivo experiments using
67

Cu were performed to study the biodistribution of 67CuCl2 and [67Cu]-DOTA in animals. In this

experiment, two groups of mice were used.One group was injected with 67Cu only and the other
group was injected with [67Cu]-DOTA. In triplicate mice were sacrificed at different time points
and organs were collected. The radioactivity of each organ was determined after normalizing all
date. Biodistribution results showed rapid clearing of both 67Cu and [67Cu]-DOTA after 6 hours,
except in the liver which slowed accumulation and slow clearance of 67Cu and [67Cu]-DOTA. This
could be due to cooper interaction and metabolism in the liver.

6.8 Fluorescence microscopy of SB2 labeled with near-infrared dye 800CW
Near-infrared dye was used as alternative to radiolabeling. In this work, SB2 was labeled
with the dye in different ratio (1:1, 1:2 and 1:3). This was done to determine the labeling yield of
different molar ratios. Results showed the increases for fluorescent signal to about 2 folds from ratio
1:1 to 1:2.and and 1 fold from ratio 1:2 to 1:3. This could be related to the saturation of binding of
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dye to lysine residues on the antibody[164]. The stability of all ratios of labeled SB2 to dye was
monitored using UV/Vis analyzer for 5 days and compared to the stability of the dye only. The
results showed that the fluorescent signals are decreasing slowly with the time. The molar ratio 1:3
of SB2 to dye was used for in vitro work to determine the binding of non-radioactive labeled SB2 to
SAS1B. Different cell lines SNU539, SK-OV3 and A549 were grown and incubated with SB2INRdye 800CW. Fluorescent signals were determined on SNU539 and SK-OV3 cells while no
signals on A549. These fluorescent signals indicate the binding of SB2 to SAS1B on SNU539 and
SK-OV3 due to the overexpression of SAS1B on these cell as reported in the UVA studies. The lung
cells A549 were used as negative control and there were no fluorescent signals determined on these
cells. Near-infrared labeling of SB2 confirms the specific binding of SB2 to its target SAS1B and
the results are encouraging for in vivo study of imaging uterine tumor and biodistribution in mouse
model. With this fluorescence labeling version of monoclonal, it is a useful additional
complementary tool to radiotracer analysis.
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CHAPTER 7: CONCLUSION AND FUTURE WORK
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7.1 Summary
Radiolabeling anti-SAS1B antibodies with 89Zr, 67Cu and near-infrared dye 800CW have
been synthesized to enable molecular imaging of the radiolabeled conjugates in uterine cancer
xenografts expressing the cell surface antigen SAS1B.
Optimizing the conjugation of the chelators of radioactive isotopes with anti-SAS1B (SB2
and SB5) and SB2 with near-infrared was performed using low scale of activity. HPLC with size
exclusion chromatography was used to determine the conjugation yield and radiochemical purity.
Radiolabeled yields of SB5 and SB2 were determined using radio-TLC analysis and then purified
using size exclusion column PD10. Labeling SB2 with near-infrared dye was determined by
UV/VIS fluorescence microscopy. In vitro study confirmed the specific binding of SB2 and SB5 to
SAS1B receptor on uterine cancer cell lines SNU539.
In vivo PET imaging of 89Zr-radiolabeled SB5, in tumor-bearing nude mice, showed some
radioactivity in the tumor, indicative of preferential accumulation, presumably due to affinity of
radiolabeled SB5 toSAS1B present on surface of tumor cells. However, conformation of binding
specificity needs to be assessed by relating radiolabeled SB5 uptake to level of SAS1B present on
the same tumor. Significant uptake was also observed in bone, a phenomenon that has been reported
in the literature of 89Zr-immunoPET imaging [165]. The explanation for bone accumulation is
probably due to detachment of the radioisotope from its DFO cage and as zirconium has affinity for
the phosphonate lattice, it accumulates in bone. Chelators other than DFO are being developed in an
attempt to reduce in vivo instability, for example the linker HOPO [166].
Preliminary in vitro experiments of radiolabeled SB2 with 67Cu demonstrated the specific
uptake of both the uterine cancer cell line SNU539 and ovarian cancer cell line SK-OV3 because
both cell lines express SAS1B. The use of [67Cu]-DOTA SB2 for future in vivo studies may provide
a better pharmacokinetic profile than that of [89Zr]-radiolabeled antibody. Successfully labeled SB2
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with the NIR dye 800CW could also be used in validation experiments as it was established that this
optical probe showed uptake of both cells SNU539 and SK-OV3 which express SAS1B compared to
a negative control, the lung cancer cell line A549 which does express SAS1B.

7.2 Future work
Future work should build on the progress made in the development of radio-immuno-conjugates and
pursue three future aims:
1. Further optimize [64/67Cu]-SB2/5 conjugation and investigate its stability, particularly in
vivo, by performing radio-HPLC analysis on homogenized tissues, including tumors.
2. Determine the amount of SAS1B in tumor sections by protein assay, and assess how this
protein level is related to uptake of radiolabeled antibody in the same tumor slice.
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